

## Curriculum Vitae

**David R. Jones, M.D.**

**George R. Minor Endowed Chair and Professor of Surgery  
Professor of Biochemistry and Molecular Genetics  
Vice-Chairman, Department of Surgery  
Division Chief, Thoracic & Cardiovascular Surgery  
Chief, General Thoracic Surgery**

### Personal Information and Education

<b>Birth date</b>	May 9, 1963
<b>Wife's Name</b>	Julie Morgan Jones, PharmD
<b>Children</b>	Abigail Morgan, September 1995 Mattie Elizabeth, August 1998
<b>Home Address</b>	3303 Rosewood Lane Charlottesville, VA 22903
<b>Business Address</b>	Thoracic & Cardiovascular Surgery University of Virginia P.O. Box 800679 Charlottesville, VA 22908-0679
<b>Business Phone</b>	(434) 243-6443
<b>FAX</b>	(434) 982-1026
<b>e-mail Address</b>	djones@virginia.edu
<b>Education</b>	May 1985      BA:      Magna Cum Laude, Chemistry West Virginia University Morgantown, WV
	May 1989      MD:      West Virginia University School of Medicine Morgantown, WV
	July 1989-June 1992      General Surgery Residency West Virginia University Hospitals Morgantown, WV
	July 1992-June 1993      General Thoracic Surgery Research West Virginia University Hospitals Morgantown, WV
	July 1994-June 1995      Chief Resident, General Surgery West Virginia University Hospitals

Morgantown, WV

July 1995-June 1998

Thoracic Surgery Residency  
University of North Carolina  
Chapel Hill, NC

July 1998-June 1999

Post-doctoral Fellowship in Molecular Oncology  
Albert S. Baldwin PhD, Mentor  
University of North Carolina, Chapel Hill, NC

### **Certifications**

Diplomate, National Board of Medical Examiners, 1989 (#378274)

Diplomate, American Board of Surgery, 1996 (#41036), (Re-certified, 2006)

Diplomate, American Board of Thoracic Surgery, 1999 (#6258), (Re-certified, 2007)

### **Medical Licensure**

Virginia #0101840486

North Carolina #98-00581 (inactive)

West Virginia #16874 (inactive)

### **Academic Appointments**

George R. Minor Endowed Professor of Surgery, Department of Surgery, University of Virginia, Charlottesville, VA (2007-present)

Vice-Chairman, Clinical Affairs and Quality, Department of Surgery, University of Virginia, Charlottesville, VA (2012-present)

Professor, Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA (2012-present)

Division Chief, Thoracic & Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, VA (2007-present)

Section Chief, General Thoracic Surgery, Department of Surgery, University of Virginia, Charlottesville, VA (2005-present)

Surgical Director, Lung Transplantation Program, University of Virginia, Charlottesville, VA (2001-2009; 2011-present)

Associate Professor of Surgery (with tenure), Department of Surgery, University of Virginia, Charlottesville, VA (2005-2007)

Assistant Professor of Surgery with term, Department of Surgery, University of Virginia, Charlottesville, VA (1999 – 2004)

Consultant, Veterans Administration Hospital, Salem VA (2001-present)

Clinical Instructor of Surgery, Department of Surgery, The University of North Carolina, Chapel Hill, NC (1998-1999)

### **Honors and Achievements**

Alpha Omega Alpha Honor Medical Society  
Phi Beta Kappa  
Alpha Epsilon Delta Pre-Medical Honor Society  
Golden Key National Honor Society  
Phi Lambda Upsilon (Chemistry Honor Society)  
First Place, 25th Annual Van Liere Medical Student Research Forum, 1989  
First Place-Annual Junior Resident Research Competition, 1990  
Third Place-Annual Junior Resident Research Competition, 1991  
First Place, 6th Annual Bernard Zimmermann Surgery Research Forum, 1993  
First Place-ACS Trauma Paper Competition, West Virginia Chapter, 1993  
Third Place, 7th Annual Bernard Zimmermann Surgery Research Forum, 1994  
Surgical Resident Research Award, 1993  
Surgical Resident Teaching Award, 1995  
2001 AACR Career Development Award for Translational Lung Cancer Research  
2002 American College of Surgeons, Virginia Chapter, Young Surgeon Award  
2003 Faculty mentor, 1<sup>st</sup> place, UVA Department of Surgery Resident Research Award (Dr. C. E. Denlinger)  
2003 University of Virginia School of Medicine Award for Clinical Excellence  
2005 University of Virginia School of Medicine Leadership in Academic Medicine (LAM) Participant  
2005 Best Doctors in America  
2006 Faculty mentor, 1<sup>st</sup> place, UVA Department of Surgery Resident Research Award (Dr. P. W. Smith)  
2006, 2007, 2008, 2009, 2010 Castle Connolly's America's Top Doctors for Cancer  
2006, 2007, 2008, 2009, 2010 Castle Connolly's America's Top Doctors  
2006 Elected to the University of Virginia Academy of Distinguished Educators  
2010 Winner Bigger-Lehman Paper, Virginia Surgical Society (Resident A. Nagji MD)  
2010 Best Doctors in Virginia and Washington DC  
2010 Distinguished Faculty Speaker Award, University of Virginia Alumni Education  
2011 AATS Grant Writing Workshop, Co-Chair

### **Editorial Boards**

1. Editorial Board, *The Annals of Thoracic Surgery* 2005-present
2. Associate Editor, *Operative Techniques in Thoracic and Cardiovascular Surgery* 2006-present
3. Editorial Board, *Cell Science Journal* 2010-2012
4. Editorial Board, *Year Book of Surgery* 2006-2010

5. Guest Editor, *Seminars in Thoracic and Cardiothoracic Surgery*, “The Molecular Biology of Lung Cancer” 2004
6. Ad hoc Reviewer
  1. *Journal of Thoracic and Cardiovascular Surgery*
  2. *International Journal of Cancer*
  3. *Lung Cancer*
  4. *Journal American College of Surgeons*
  5. *Modern Pathology*
  6. *Annals of Surgical Oncology*
  7. *Clinical Lung Cancer*
  8. *Molecular and Cellular Biology*
  9. *Oncogene*
  10. *Chest*
  11. *Cancer Investigation*
  12. *World Journal of Surgical Oncology*
  13. *Cancer Letters*
  14. *Journal of Thoracic Oncology*
  15. *Endocrine-Related Cancer*
  16. *Clinical and Experimental Metastases*
  17. *Molecular Pharmacology*
  18. *Experimental Cell Research*
  19. *Annals of Surgery*
  20. *Surgery*
  21. *FEBS Journal*
  22. *Journal of Cellular and Molecular Medicine*
  23. *Carcinogenesis*
  24. *Journal of Surgical Oncology*

#### **Department of Surgery Committees and Appointments**

1. Surgical Director, UVA Lung Transplantation Program, 2001-2008, 2011-present
2. Medical Director, Thoracic Cardiovascular Surgery Intensive Care Unit, 1999 – 2010
3. Associate Program Director, UVA Thoracic Surgery Residency Program, 2004-present
4. Member, Department of Surgery Finance Committee 2004-2005
5. Section Chief, General Thoracic Surgery, 2005-present
6. Faculty Advisory Committee for Research, 2007-present
7. Chairman, Local Arrangements Committee, Muller-Jones Surgical Society, 2006-2009
8. Division Chief, Thoracic & Cardiovascular Surgery, 2007-present
9. Southern Society of Clinical Surgeons, Local Program Planning Chairperson, 2007-08
10. Vice-Chairman, Department of Surgery, 2012-present
11. Chair, Billing and Compliance Committee, 2012-present

#### **School of Medicine and UVA Hospital Committees**

1. Member, UVA Cancer Registry Committee, 1999 – 2004
2. Member, UVA Clinical Cancer Center, 1999 – present

3. Member, UVA Cancer Center Protocol Review Committee, 2000 – 2004
4. Member, Critical Care Committee, 2000 – 2010
5. Member, Faculty Development Council, 2001
6. Member, General Clinical Research Center Committee, 2002- 2004
7. Member, Internal Scientific Advisory Committee, UVA Cancer Center, 2002-present
8. Program Leader, Thoracic Oncology Program, UVA Cancer Center 2003-present
9. Member, Research Advisory Committee (RAC), UVA School of Medicine, 2003-2004
10. Chair, Thelma R. Swortzel Award Committee 2004
11. Member, UVA Cancer Center Oncology Imaging Subcommittee, 2004
12. UVA Clinical Excellence Award selection committee, 2005, 2006
13. Chair, Horsely Prize Committee, UVA School of Medicine, 2006
14. UVA Hospital, Cancer Committee, 2007
15. UVA Hospital, Nominating Committee, 2007-present
16. UVA Operating Room Committee, 2009-present
17. Billing Quality Oversight Committee 2012-present
18. Clinical Staff Executive Committee, 2012-present

#### **Faculty/Chair Search Committees**

1. Member, Search Committee for the Chair of the Department of Molecular Physiology & Biological Physics 2006
2. Member, Dean's Chair Review Committee, Department of Pathology, 2006
3. Member, Search Committee for the Chair of the Department of Microbiology 2010
4. Member, Department of Surgery, Division of Thoracic & Cardiovascular Surgery searches (2006, 2007, 2009, 2011, 2012). Total of 7 faculty.
5. Co-Chair, Dean's Search for Director, Virginia Center for Translational and Regulatory 2012

#### **Business Opportunities**

1. Diffusion Pharmaceuticals, LLC, Charlottesville, VA. Chief Medical Officer and Scientific Advisory Board 2009-present.

#### **Professional Associations and Societies**

American Association of Thoracic Surgery  
American Surgical Association  
Society of Thoracic Surgeons  
Society of Clinical Surgeons  
Southern Surgical Association  
Halsted Society  
Society of University Surgeons  
American Society of Clinical Oncology  
American Association of Cancer Research  
General Thoracic Surgery Club  
European Society of Thoracic Surgeons  
American College of Chest Physicians  
American College of Surgeons

Society of Thoracic Surgical Education  
International Association for the Study of Lung Cancer  
Southern Thoracic Surgical Association  
General Thoracic Surgery Biology Club  
International Society of Heart and Lung Transplantation  
Association for Academic Surgery  
American Thoracic Society  
Virginia Surgical Society  
Medical Society of Virginia  
Nathan S. Womack Surgical Society  
Muller-Jones Surgical Society

**International, National and Regional Committees**

Thoracic Surgery Director's Association resident representative to the Organization of Resident Representatives of the American Association of Medical Colleges (AAMC)	1993 -1996
Member, AAMC Graduate Educational Affairs	1999-present
American College of Chest Physicians (ACCP) Expert Panel on Lung Cancer Guidelines	2001 - present
Society of Thoracic Surgeons (STS), Committee on Workforce Publications (Chairperson 2005 - 2010)	2003 - 2010
International Association for the Study of Lung Cancer, Vetting Committee	2003 - present
Commonwealth of Kentucky Lung Cancer Research Program Grant Review Panel	2003 – present
Southern Thoracic Surgical Association, Postgraduate Committee (Co-Chairperson 2005)	2003 - 2005
Virginia Thoracic Society, Program Committee	2004 – 2005
American College of Surgeons Oncology Group (ACOSOG) - Head, Thoracic Surgery Basic Science Committee	2004 - 2008
American College of Surgeons Oncology Group (ACOSOG) - Thoracic Organ Site Core Committee	2004 - 2008
Thoracic Surgery Research Foundation for Research and Education (TSFRE) - Research Committee	2004 - 2011
Associate Program Director, Thoracic Surgery Director's Association (TSDA), University of Virginia Thoracic Surgery Residency Program	2004 - present

Society of Thoracic Surgeons, Council on Education and Member Services	2004 - present
Southern Thoracic Surgical Association, Continuing Medical Education Committee	2004 - present
Self-Education/Self-Assessment in Thoracic Surgery (SESATS) SESATS IX, General Thoracic Surgery committee member	2004 - 2005
American Board of Thoracic Surgery (ABTS) Examination Consultant Committee, General Thoracic Subcommittee	2005 - 2010
Society of Thoracic Surgeons, Program Vetting Committee	2005 - present
American Association of Thoracic Surgery, Program Vetting Committee	2006 – present
American Board of Thoracic Surgery (ABTS) Certifying Examination Consultant – Ad Hoc oral board examiner	2005 - 2010
Thoracic Surgery Research Foundation for Research and Education (TSFRE) - Research Committee; Chairman	2007 - 2011
American Association of Thoracic Surgery, Evarts Graham Memorial Travel Fellowship Committee	2005 - 2009
American Association of Thoracic Surgery, Membership Committee	2006 - 2010
American Association of Thoracic Surgery, Chair Membership Committee	2008 - 2010
American Association of Thoracic Surgery, Scientific and Government Relations Committee	2006 - present
European Society of Thoracic Surgeons; Ad Hoc Committee for Technologic Advancements	2007 - 2011
Society of Thoracic Surgeons, Workforce on Annual Meeting (Program Task Force)	2007 - 2010
Society of Thoracic Surgeons, Workforce on Annual Meeting (Chairman)	2009-2010
European Society of Thoracic Surgeons; Program Committee	2007 - 2010
American College of Surgeons, Executive Committee, Annual Program Planning	2007 – 2013
STS/AATS Health Policy, Reform, & Advocacy Committee	2008-2014

Councilor, Southern Thoracic Surgical Association	2008-2010
Member, Cancer Genome Atlas Pilot Project (NCI)	2008-present
Board of Directors, Thoracic Surgery Foundation for Research & Education	2011-present
AATS/STS Annual Meeting Liaison	2009-2012
AATS Education Committee/Post-Graduate Advisory Subcommittee	2009-2012
Chair, Society of Thoracic Surgeons, Council on Education and Member Services	2010-2012
AATS Program Committee	2010-present
AATS Scientific and Government Relations Committee (Co-Chair)	2010-present
Secretary-Treasurer, Southern Thoracic Surgical Association	2010-2014
Co-Chair, ESTS-AATS-STS Postgraduate Course in Thoracic Surgery	2010
Chair, AATS General Thoracic Surgery Symposium	2011
Co-Chair AATS Grantsmanship Course	2011
TSFRE, Finance Committee	2010-14
Society of Thoracic Surgeons, Workforce on Research Development	2011-14
Director, American Board of Thoracic Surgery	2010-16

### **Visiting Professorships/Invited Lectures**

Washington University, Contemporary General Thoracic Surgery Invited Lecturer	2006
West Virginia University, Department of Surgery Visiting Professor	2007
Massachusetts General Hospital, Visiting Research Professor	2007
Taiwan Surgical Association, Keynote lecturer	2007
XXXVI Brazilian Pneumology and Thoracic Surgery Conference, Invited Lecturer	2008
Memorial Sloan Kettering Cancer Center, Department of Surgery Visiting Professor	2008
Massachusetts General Hospital, Earle Wilkins Visiting Professor	2009
Duke University, Department of Surgery	2010
European Society of Thoracic Surgeons, Valladolid, Spain; Invited Lectureship	2010
University of Toronto, Thoracic Surgery Refresher Course, 35 <sup>th</sup> RD Henderson Lecturer	2010
Mount Sinai Medical Center, Department of Surgery, New York, NY	2010
Northwestern University School of Medicine, 18 <sup>th</sup> Shield's Lectureship, Chicago, IL	2011
Columbia University, Department of Surgery, New York, NY	2011



## **Research Grants**

### **Current Funding:**

1. **NIH/NCI** (R01 CA136705). Epigenetic and post-translational regulation of the metastasis suppressor BRMS1. David R. Jones (PI). Funding period: 07/01/09 – 06/30/14.
2. **NCI** (T32 CA163177) **Postdoctoral Training Grant for MDs in Surgical Oncology Research**. David R. Jones MD, Craig L. Slingluff MD, co-PIs. 09/20/11-08/31/16.
3. **DOD** (LC090640) - A Medical Center Network for Optimized Lung Cancer Biospecimen Banking David R. Jones (co-PI). Funding period: 09/01/10 – 08/31/14.
4. **NIH/NCI** (R01 CA104397) Role of IKK in NSCLC Modulation of SMRT and NF- $\kappa$ B. Marty W. Mayo PhD (P.I.); David R. Jones, MD (co-investigator). Funding Period: 01/01/04-02/28/14.
5. **NIH/NHLBI**. (R01 HL059337) S-nitrosothiol breakdown by airway epithelial cells. Ben Gaston MD (P.I.); David R. Jones, MD (co-investigator). Funding Period: 03/01/08-12/31/12.
6. **NIH Program Project Grant PO1**. Cellular S-nitrosothiol signaling in respiratory biology. Ben Gaston MD (P.I.); David R. Jones, MD (co-investigator). Funding Period: 4/01/2011-3/31/2016.
7. **Commonwealth Foundation for Cancer Research**. Combined inhibition of histone deacetylase and proteasome activity in non-small cell lung cancer: A potentially novel treatment strategy. David R. Jones, MD, Principal Investigator. Funding period: 07/01/03-06/30/12.
8. **University of Virginia Tobacco Research Program**. Characterization and functional significance of a novel E3 ligase function of BRMS1 in governing tumorigenesis and metastasis in lung cancer. David R. Jones, MD, Principal Investigator. Funding period: 09/01/08-08/31/12.

### **Prior Funding:**

1. **NIH/NCI** (R21 HL098845-01) Predicting the lung ventilation change caused by radiation. Dr. Ke Sheng, PhD (P.I), David R. Jones MD (co-investigator). Funding period: 3/01/10-2/28/11.
2. **Thoracic Surgery Foundation for Research and Education**. “Effect of combined histone deacetylase inhibitors and proteasome inhibitors on epithelial-mesenchymal-transition in non-small cell lung cancer. Alykhan S. Nagji, Surgery Resident, David R. Jones MD, Scientific mentor. Funding period 07/01/09-06/30/10.

3. **University of Virginia Farrow Fellowship.** Mechanisms of Post-translational Regulation of the Metastasis Suppressor BRMS1 in Non-Small Cell Lung Cancer. Matthew D. Taylor, MD, Principal Investigator; Scientific Mentor: David R. Jones, MD. Funding period 06/01/07-05/31/08.
4. **University of Virginia Cancer Center, Innovative Grants Program.** Identification of Lung Cancer Biomarkers through Epigenetics. Marty W. Mayo (PI), David R. Jones (co-PI). Funding period 03/01/08-02/28/09.
5. **NIH/NCI (K08 CA83920) NIH/NCI Mentored Clinician-Scientist Developmental Award.** NF- $\kappa$ B mediated chemoresistance in human lung cancer. University of Virginia, David R. Jones, MD, Principal Investigator. Funding period: 8/1/00 – 06/30/06.
6. **University of Virginia Cancer Center, Innovative Grants Program.** The role of the Metastasis Suppressor BRMS1 in Modulating Transcriptional Activity of NF- $\kappa$ B in Non-Small Cell Lung Cancer. David R. Jones, MD, Principal Investigator. Funding period 06/01/06-05/31/07.
7. **NRSA/NCI (NCI F32 CA101497)** Loss of NF-kappa B enhances apoptosis by HDAC inhibitors. Scientific mentor and sponsor for Chad Denlinger, MD. Funding Period: 07/01/03-06/30/04.
8. **Millennium Pharmaceuticals, Cambridge, MA.** Proteasome inhibition and chemotherapy as novel treatment in non-small cell lung cancer. David R. Jones, MD, Principal Investigator. Funding period 04/01/03-03/31/06.
9. **American Association of Cancer Research (AACR) Career Development Award in Translational Lung Cancer Research.** Chemosensitization of non-small cell lung cancer through inhibition of NF- $\kappa$ B. David R. Jones, MD, Principal Investigator. Funding Period: 07/01/01-06/30/03.
10. **American Cancer Society IRG 81-001-17,** University of Virginia. Role of Rac/ROS signal transduction in chemotherapy-induced NF- $\kappa$ B activation in non-small cell lung cancer. David R. Jones, MD Principal Investigator. Funding period: 3/15/00 – 6/30/01.
11. **Jeffress Memorial Trust.** Role of Bcl-X<sub>L</sub> in the chemosensitization of non-small cell lung cancer following the inactivation of NF- $\kappa$ B. David R. Jones, MD Principal Investigator. Funding Period: 1/1/01-12/31/01.
12. **Bristol-Myers Squibb Oncology.** Combined Paclitaxel chemotherapy and gene therapy-induced inhibition of NF- $\kappa$ B for non-small cell lung and esophageal cancer. David R. Jones, MD, Principal Investigator. Funding Period: 6/1/00- 5/31/03.
13. **University of North Carolina Lineberger Comprehensive Cancer Center Clinical Research Award.** Effect of induction chemoradiotherapy on p53, Cyclin D, Rb, and

Bcl-2 oncoprotein expression in esophageal carcinoma. David R. Jones, MD, Principal Investigator. Funding period: 4/15/96 - 3/31/97.

14. **Medical Alumni Endowment Fund**, University of North Carolina. Effects of Isoproterenol, Rolipram, and hyperoxia on ischemia-reperfusion lung injury. David R. Jones, MD Principal Investigator. Funding period: 7/1/96 - 6/30/97.

**Research residents/students trained:**

Chadrick E. Denlinger, MD	University of Virginia General Surgery Resident NRSA award (NCI F32 CA101497) Loss of NF-kappa B enhances apoptosis by HDAC inhibitors	(2002-2004)
Brian K. Rundall, DO	Western Reserve Care System, Youngstown, Ohio General Surgery Resident	(2003-2005)
Michael D. Keller, BS	Undergraduate student University of Virginia Matriculated to Duke University Medical School	(2002-2003)
Ann Bryon Vaughters, BS	Medical Student (MS I) University of Virginia MSSRP, Summer Research Oncology Fellowship	(2004)
Vamsi Parmi, MD	University of Mississippi, Jackson, MS Post-Doctoral Fellow Summer Research Fellowship	(2005)
Phillip W. Smith, MD	University of Virginia General Surgery Resident	(2005-2007)
Yuan Liu, MD, PhD	University of Virginia Post-Doctoral Fellow	(2005-present)
Nicholas Theodosakis	University of Virginia Undergraduate student	(2006-2008)
Janine L. Oliver, BS	Medical Student (MS I) University of Virginia MSSRP, Summer Research Oncology Fellowship	(2007)
Matthew D. Taylor, MD	University of Virginia General Surgery Resident	(2007-2009)

Alykhan S. Nagji, MD	University of Virginia General Surgery Resident	(2008-2010)
Christina Wei, MD	University of California, San Francisco General Surgery Resident	(2010-2011)
Caleb Anderson	Medical Student (MS I) University of Virginia MSSRP, Summer Research Oncology Fellowship	(2010)
Jason Nellis	Medical Student (MS I) University of Virginia MSSRP, Summer Research Oncology Fellowship	(2010)
Lauren Simpkins	University of Virginia Undergraduate student	(2011)

### **Extramural Study Sections**

1. NIH/NCI Tumor Progression and Metastasis (TPM), Permanent member 2011-16.
2. NIH/NCI Cancer Molecular Pathobiology (CAMP), Ad Hoc Member 2010
3. NIH/NCI SPORE (Specialized Programs of Research Excellence), Lung Cancer Programs; Member, 2008-present.
4. NIH/NCI. Surgical Sciences, Biomedical Imaging, and Bioengineering IRG [SBIB], Ad Hoc Member, 2008.
5. Commonwealth of Kentucky Lung Cancer Research Program; Member, Grant Review Panel, 2003-present.

### **Clinical trials**

#### **Principal Investigator:**

1. **Jones DR.** A Phase I study of induction therapy with Velcade and Vorinostat in patients with surgically resectable non-small cell lung cancer. (*Investigator-initiated, UVA only*)
2. **Jones DR.** A phase I trial of intrapleural Docetaxel administered via an implantable catheter in patients with malignant pleural effusions. Aventis Pharmaceuticals, Bridgewater, NJ. (*investigator-initiated, UVA only*) (closed)

3. **Jones DR.** A randomized phase III study of sublobar resection versus sublobar resection Plus brachytherapy in high-risk patients with non-small cell lung cancer (NSCLC), 3cm or smaller (Z4032). American College of Surgeons Oncology Group. (closed)
4. **Jones DR.** A Randomized Phase III Trial Of Adjuvant Chemotherapy In Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking Of Frozen Tumor Specimens And Collection Of Gene Expression Profile Data (CALGB 30506). PI for the American College of Surgeons Oncology Group.
5. **Jones DR.** A multi-center, single blind, randomized study comparing thymectomy to no thymectomy in non-thymomatous myasthenia gravis patients on prednisone. NINDS. (UVA primary surgical investigator).
6. **Jones DR.** Thoracic oncology tissue bank for lung and esophageal malignancies. UVA Clinical Cancer Center.
7. **Jones DR.** A phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer. (ECOG 5597) (closed)
8. **Jones DR.** Use of proteomic analysis of serum samples for detection of non-small cell lung cancer (Z4031). American College of Surgeons Oncology Group. (closed)
9. **Jones DR.** Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell lung cancer (Z0030). American College of Surgeons Oncology Group. (closed)
10. **Jones DR.** A prospective study of the prognostic significance of occult metastases in the patient with respectable non-small cell cancer (Z0040). American College of Surgeons Oncology Group. (closed)
11. **Jones DR.** Thorex Lung Sealant: A prospective, randomized clinical trial. Surgical Sealants, Inc. Boston, MA. (closed)

Co-Investigator:

1. **Jones DR.** (E1505), A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB-III A Non-Small Cell Lung Cancer (NSCLC). Principal Investigator: Tom Harris MD.
2. **Jones DR.** A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer. Principal Investigator: Benjamin D. Kozower, MD.
3. **Jones DR.** Pilot Study of MRI for Evaluation of Respiratory Tumor Motion and for Determination of Vasculature Effects of Radiation. Principal Investigator: Paul Read MD, PhD.

4. **Jones DR.** Single Arm Feasibility/Tolerability Study for Non-Operable Stage T1a-T2b, N0, M0 Non-Small Cell Lung Cancers (NSCLC), Treated With Stereotactic Body Radiation (SBRT) and Carboplatin/Paclitaxel. Principal Investigator: Tom Harris MD
5. **Jones DR.** A multi-center, randomized, double-blind, placebo-controlled, parallel design, 2-arm study to investigate the effect of aprotinin on transfusion requirements in patients undergoing surgical procedures for lung cancer or esophageal cancer. Bayer, Inc. Principal Investigator: K. Robert Shen MD. (closed)
6. **Jones DR.** Human gene expression project. Virginia Tobacco Settlement Foundation. Principal Investigator: Chris Moskaluk MD, PhD.
7. **Jones DR.** Phase II Study of Docetaxel and Thalidomide as Second-line Treatment for Non-Small Cell Lung Cancer. Principal Investigator: Heidi Gillenwater, MD (closed).
8. **Jones DR.** Regulation of human lung mast cells by adenosine. Principal Investigator: Joel Linden, PhD (closed)
9. **Jones DR.** A Randomized, Comparative, Single-Blind Clinical Trial to Evaluate the use of Vivostat System Fibrin Sealant as an Adjunct to Sutures and Staples in Controlling Air Leak after Lung Resection. Convatec Inc. Principal investigator: Tom Daniel MD (closed)

### **Bibliography**

1. **Jones DR,** Hill RC, Vasilakis A, Femovich DA, Arsenault P, Abbott A, Docherty R. The successful resuscitation of a hypothermic multitrauma patient. WV St Med J 1991; 87:298-301.
2. **Jones DR,** Vaughan RA, Timberlake GA. Pancreatic pseudocyst: Diagnosis and management. South Med J 1992; 85:729-34.
3. **Jones DR,** Vasilakis A, Pillai L, Timberlake GA. Giant, benign, mucinous cystadenoma of the ovary: Case study and literature review. Am Surg 1992; 58:400-3.
4. **Jones DR,** Hill RC, Abbott AE Jr., Gustafson RA, Murray GF. Unusual location of an atrial myxoma complicated by a secundum atrial septal defect. Ann Thorac Surg 1993; 55:1252-3.
5. **Jones DR,** Hill RC, Hollingsed MJ, Stullken E, Graeber GM, Gustafson RA, Murray GF. Utilization of heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1993; 56:566-8.
6. **Jones DR,** Graeber GM, Tanguilig GG, Hobbs G, Murray GF. Effects of insufflation on hemodynamics during thoracoscopy. Ann Thorac Surg 1993; 55:1379-82.
7. Tanguilig GG, **Jones DR,** Graeber GM. Video-assisted thoracoscopy: A significant advance in diagnosis and treatment of intrathoracic pathology. WV St Med J 1993; 89:230-2.

8. Graeber GM, **Jones DR**. The role of thoracoscopy in thoracic trauma. Ann Thorac Surg 1993; 56:646-8.
9. **Jones DR**, Hill RC, Heiskell CA, Hollingsed MJ, O'Keefe M, Nelson MG. Coronary-subclavian steal with concomitant carotid disease: Indication for axilloaxillary bypass. Vasc Surg 1994; 28:51-6.
10. **Jones DR**, Davidson AG, Summers CL, Murray GF, Quinlan DC. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 1994; 57:598-603.
11. **Jones DR**, Hill RC, Vasilakis A, Hollingsed M, Gustafson RA, Graeber GM, Murray GF. Safe utilization of heparin coated bypass circuits incorporating a pump-oxygenator. Ann Thorac Surg 1994; 57:815-9.
12. Nelson MG, **Jones DR**, Vasilakis A, Timberlake GA. Computed tomographic diagnosis of acute blunt pancreatic transection. WV St Med J 1994; 90:274-8.
13. **Jones DR**, Vasilakis A, Wearden PD, Nelson MG, Morales JM, Graeber GM, Murray GF. Technique for management of an axilloaxillary bypass complicating a median sternotomy. J Cardiovasc Surg 1994; 35:235-7.
14. **Jones DR**, Tanguilig GG, Graeber GM. Thoracoscopic resection of bilateral metastatic sarcomas causing spontaneous pneumothoraces. Chest 1994; 106:1274-6.
15. Hill RC, Kalantarian B, **Jones DR**. Use of microfibrillar collagen hemostat (Avitene) and thrombin to achieve hemostasis post median sternotomy. J Thorac Cardiovasc Surg 1994; 108:1151-2.
16. **Jones DR**, Graeber GM, Tanguilig GG, Hobbs G, Murray GF. Effects of insufflation on hemodynamics during thoracoscopy. Year Book of Surgery. St. Louis: Mosby-Yearbook, 1994; 468-9.
17. **Jones DR**, Abbott AE Jr, Hill RC, Beamer KC, Gustafson RA, Murray GF. Preservation of ATP and mitochondrial function during hypercalcemic reperfusion using verapamil cardioplegia. Chest 1995; 107:307-10.
18. **Jones DR**, Warden HE, Murray GF, Hill RC, Cruzzavala J, Gustafson RA, Graeber GM, Vasilakis A. Biatrial approach to cardiac myxomas: A 30-year clinical experience. Ann Thorac Surg 1995;59:851-6.
19. Murray GF, **Jones DR**, Stritter FT. A comprehensive curriculum for thoracic surgery: Survey of opinions from program directors and residents. Ann Thorac Surg 1995; 60:877-87.
20. **Jones DR**, Davidson AG, Summers CL, Murray GF, Quinlan DC. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Year Book of Digestive Diseases. Chicago: Mosby, 1995; 30-2.

21. Hill RC, **Jones DR**, Kalantarian B, Vance RA. Selective lung ventilation during thoracoscopy: Effects of insufflation on hemodynamics. Ann Thorac Surg 1996; 61:945-8.
22. **Jones DR**, Dupras D, Ruffin AL. Importance of the perspective of residents in defining and maintaining quality in GME. Acad Med 1996; 71:820-2.
23. **Jones DR**, Hoffmann SC, Sellars M, Egan TM. Reduced ischemia-reperfusion injury with isoproterenol in non-heart beating donor lungs. J Surg Res 1997; 69:385-92.
24. **Jones DR**, Becker RM, Hoffmann SC, Lemasters JJ, Egan TM. When does the lung die?-changes in Kfc, cell viability, and adenine nucleotide levels in the circulation-arrested rat lung. J Appl Physiol 1997; 83:247-52.
25. **Jones DR**, Detterbeck FC, Egan TM, Parker LA Jr, Bernard SA, Tepper JE. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 1997; 64:185-92.
26. Wilcox BR, **Jones DR**, Frantz EG, Brink LW, Henry GW, Mill MR, Anderson RH. An anatomically sound, simplified approach to repair of "complete" atrioventricular septal defect. Ann Thorac Surg 1997; 64:487-94.
27. **Jones DR**, Detterbeck FC. Pancoast tumors of the lung. Current Opin Pulm Med 1998; 4:191-97.
28. **Jones DR**, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal cancer after induction chemoradiotherapy. Cancer 1999;85:1026-32.
29. Bleiweis MS, **Jones DR**, Hoffmann SC, Becker RM, Egan TM. Reduced ischemia-reperfusion injury with rolipram in rat cadaver lung donors: effect of cyclic adenosine monophosphate. Ann Thorac Surg 1999;67:194-200.
30. **Jones DR**, Guy JS, Mill MR, Baker CC. Retrograde arterial bullet embolus to a coronary artery: case report. J Trauma 1999;46:1135-1136.
31. **Jones DR**, Mayo MW, Marshall A, Baldwin AS. Chemosensitivity in NSCLC by NF- $\kappa$ B inhibition is Fas-independent. Surg Forum 1999;L:152-54.
32. **Jones DR**, Broad RM, Madrid LD, Baldwin Jr. AS, Mayo MW. Inhibition of NF- $\kappa$ B sensitizes non-small cell lung cancer to chemotherapy-induced apoptosis. Ann Thorac Surg 2000;70:930-37.
33. **Jones DR**, Broad RM, Parsons SJ, Mayo MW. Chemotherapy-induced reactive oxygen species activate NF- $\kappa$ B and are required to induce apoptosis following the loss of NF- $\kappa$ B in NSCLC. Surg Forum 2000;LI:140-142.



34. Hoffman SC, Bleiweis MS, **Jones DR**, Paik HC, Ciriaco P, Egan TM. Maintenance of cAMP in non-heart-beating donor lungs reduces ischemia-reperfusion injury. Am J Respir Crit Care Med 2001;163:1642-7.
35. El-Rifai W, Frierson HF, Moskaluk CA, Harper JC, Petroni G, Bissonette E, **Jones DR**, Knuutila, Powell SM. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterol 2001;121:592-8.
36. Fiser SM, Kron IL, Long SM, Kaza AK, Kern JA, Cassada DC, **Jones DR**, Robbins MC, Tribble CG. Influence of graft ischemic time on outcomes following lung transplantation. J Heart Lung Transplant 2001; 20:1291-6.
37. Broad RM, Mayo MW, **Jones DR**. Paclitaxel-mediated induction of NF- $\kappa$ B is a marker of chemoresistance in esophageal cancer cell lines. Surg Forum 2001; LII: 110-2.
38. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, **Jones DR**, Robbins MK, Kron IL. Ischemia-reperfusion injury following lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002;73:1041-8.
39. **Jones DR**, Broad, Parsons SJ, Mayo MW. Inhibition of NF- $\kappa$ B chemosensitizes non-small cell lung cancer via cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 2002; 123:310-7.
40. Mayo MW, Madrid LV, Westerheide SD, **Jones DR**, Yuan XJ, Baldwin AS, Whang YE. PTEN blocks TNF-induced NF- $\kappa$ B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 2002;277:11116-25.
41. Maxey TS, Smith CD, Kern JA, Tribble CG, **Jones DR**, Kron IL, Crosby IK. Beneficial effects of inhaled nitric oxide in adult cardiac surgery patients. Ann Thorac Surg 2002; 73: 529-33.
42. Kaza AK, Dietz JF, Kern JA, **Jones DR**, Robbins MK, Fiser SM, Long SM, Bergin JD, Kron IL, Tribble CG. Coronary risk stratification in patients with end-stage lung disease. J Heart Lung Transplant 2002;21:334-9.
43. Stiles BM, Isaacs RB, Daniel TM, **Jones DR**. Role of surgery in *rhodococcus equi* pulmonary infections. J Infection 2002;45:59-61.
44. Denlinger CE, Egan TM, **Jones DR**. Acquired systemic-to-pulmonary arteriovenous malformation secondary to *M. Tuberculosis* empyema. Ann Thorac Surg 2002;74:1229-31.
45. **Jones DR**, Stiles BM, Denlinger CE, Antippa P, Daniel TM. Pulmonary segmentectomy: results and complications. Ann Thorac Surg 2003;76:343-9.
46. Detterbeck FC, **Jones DR**, Kernstine KH, Naunheim KS. ACCP Guidelines for lung cancer patients: Special treatment issues. Chest 2003;123:244-258S.

47. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, **Jones DR**. Ineffectiveness of HDAC inhibitors to induce apoptosis involves the transcriptional activation of NF- $\kappa$ B through the Akt pathway. J Biol Chem 2003;278:18980-9.
48. Denlinger CE, Keller MD, Mayo MW, Broad RM, **Jones DR**. Combined histone deacetylation and proteasome inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 2004;127:1078-86.
49. Daniel TM, Altes TA, Williams MB, **Jones DR**, Stolin AV, Gay SB. A Novel Technique for Localization and Excisional Biopsy of Small or Ill-defined Pulmonary Lesions Ann Thorac Surg 2004;77:1756-62.
50. Denlinger CE, Rundall BK, **Jones DR**. Modulation of anti-apoptotic cell-signaling pathways in non-small cell lung cancer: The role of NF- $\kappa$ B. Semin Thorac Cardiovasc Surg 2004;16:28-39.
51. Denlinger CE, Rundall BK, Kellers MD, **Jones DR**. Proteasome inhibition sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004;78:1207-14.
52. Rundall BK, Denlinger CE, **Jones DR**. Combined histone deacetylase and NF- $\kappa$ B inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004;136:416-25.
53. Yeung F, Hoberg JE, Ramsey C, Keller M, **Jones DR**, Frye RA, Mayo MW. Modulation of NF- $\kappa$ B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO 2004;23:2369-80.
54. Denlinger CE, Rundall BK, **Jones DR**. Proteasome inhibition sensitizes NSCLC to HDAC inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004;128:480-8.
55. Rundall BK, Denlinger CE, Parrino GP, Foley EF, **Jones DR**. Gastrointestinal reconstruction following laparoscopic gastric bypass surgery complicated by gastric pouch necrosis. J Gastrointest Surg 2005;9:938-40.
56. Rundall BK, Denlinger CE, **Jones DR**. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 2005;138:360-7.
57. Denlinger CE, Rundall BK, **Jones DR**. Inhibition of PI3K/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J Thorac Cardiovasc Surg 2005;130:1422-9.
58. Allen MS, Darling GE, Pechet TVT, Mitchell JD, Herndon II JE, Landreneau RJ, Inculet RI, **Jones DR**, Meyers BF, Putnam JB, Rusch VW and the ACOSOG Z0030 study group. Morbidity and mortality of major pulmonary resections in patients with early stage lung cancer:

- Initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006;81:1013-20.
59. **Jones DR**, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB non-small cell lung cancers: Are they all the same? Ann Thorac Surg 2006;81:1958-62.
  60. Zaman K, Hanigan M, Smith A, Vaughan J, McDonald T, **Jones DR**, Hunt J, Gaston B. Endogenous S-glutathione modifies 5-lipoxygenase expression in airway epithelial cells. Am J Resp Cell Mol Biol 2006; 34:387-93.
  61. **Jones DR**, Vaughters ABR, Smith PW, Daniel TM, Shen KR, Heinzmann JL. An economic assessment of the general thoracic surgery outpatient service. Ann Thorac Surg 2006;82:1068-72.
  62. Smith PW, Parini V, Zolak JS, Daniel TM, Shen KR, Robbins MK, Tribble CG, Kron IL **Jones DR**. Lung transplantation in patients 60 years and older: results, complications, and outcomes. Ann Thorac Surg 2006;82:1835-41.
  63. Stiles BM, Altes TE, **Jones DR**, Shen KR, Gay SB, Olazagasti J, Rehm PK, Daniel TM. Clinical experience with radiotracer-guided thoracoscopic biopsy of small, indeterminate lung nodules. Ann Thorac Surg 2006;82:1191-7.
  64. Smith RL, Zorn GL, Peeler BB, **Jones DR**. Combined bronchial sleeve resection and repair of partial anomalous pulmonary venous return. J Thorac Cardiovasc Surg 2006;132:982-3.
  65. Smith PW, Denlinger CE, **Jones DR**. Novel targeted therapies for non-small cell lung cancer. Thorac Surg Clin 2006;16:353-66.
  66. Liu Y, Denlinger CE, Rundall BK, Smith PW, **Jones DR**. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300 which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 2006;281:31359-68.
  67. Liu Y, Smith PW, **Jones DR**. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing HDAC-1 mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol 2006;26:8683-96.
  68. Shen KR, Meyers BF, Lerner JM, **Jones DR**. Special treatment issues. Chest 2007;132:290S-305.
  69. Shami V, **Jones DR**, Stelow EB. Esophageal leiomyosarcoma diagnosed by EUS-FNA. Diagn Cytopathol 2007;35:167-70.
  70. Hernandez, AJ, Kahaleh M, Olazagasti J, **Jones DR**, Daniel T, Stelow E, White GE, Shami VM. EUS-FNA as the Initial Diagnostic Modality in Centrally Located Primary Lung Cancers. J Clin Gastroenterol 2007;41:657-60.

71. Smith PW, Hongkun Wang H, Gazoni LM, Shen KR, Daniel TM, **Jones DR**. Obesity Does Not Increase Complications After Anatomic Resection For Non-Small Cell Lung Cancer. Ann Thorac Surg 2007;84:1098-106.
72. Baisden JM, Romney DA, Reish AG, Cai J, Sheng K, **Jones DR**, Benedict SH, Read PW, Lerner JM. Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors. Int J Radiat Oncol Biol Phys 2007;68:1229-37.
73. Serra C, Palacios D, Mozetta C, Forcales S, Morantte I, Ripani M, **Jones DR**, Du K, Jhala US, Simone C, Puri PL. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell 2007;28:200-13.
74. **Jones DR**, Daniel TM, Denlinger CE, et al. Stage IB nonsmall cell lung cancers: Are they all the same? Year Book of Surgery. St. Louis: Mosby-Yearbook, 2007, 390-1.
75. Smith PW, Wang H, Parini V, Zolak JS, Daniel TM, Shen KR, Robbins MK, Tribble CG, Kron IL **Jones DR**. Lung transplantation in patients 60 years and older: results, complications, and outcomes. Year Book of Surgery. St. Louis: Mosby-Yearbook, 2007, 405-7.
76. Grogan E, **Jones DR**, Kozower BD, Simmons WD, Daniel TM. Identification of small lung nodules - technique of radiotracer guided thoracoscopic biopsy. Ann Thorac Surg 2008;85:S772-77.
77. Taylor MD, Nagli AS, Kozower BD, Daniel TM, **Jones DR**. Intermediate results of primary and redo transthoracic repairs of paraesophageal hernias. Inter Cardiovasc Thorac Surg 2008;7:71-4.
78. Kozower BD, Meyers BF, Smith MA, DeOliveiria NC, Cassivi SD, Guthrie TJ, Conaway MR, Ryan BJ, Shen KR, **Jones DR**. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter review. J Thorac Cardiovasc Surg 2008;135:166-71.
79. Ailawadi G, Smith PW, Oka T, Wang H, Kozower BD, Daniel TM, Kron IL, **Jones DR**. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008;135:594-602..
80. Shami VS, **Jones DR**, Hernandez A, Stelow EB. Endoscopic ultrasound-guided fine needle aspiration of a malignant pleural effusion to diagnose and stage lung cancer: when should this approach be considered? Digest Dis Sci 2008;53:757-9.
81. Kozower BD, Meyers BF, Reed CE, **Jones DR**, Decker PA, Putnam JB. Does positron emission tomography prevent nontherapeutic thoracotomies for clinical stage IA lung cancer? Ann Thorac Surg 2008;85:116-70.
82. McDonough PB, **Jones DR**, Shen KR, Northup PG, Galysh RL, Hernandez A, White GE, Kahaleh M, Shami VS. Does FDG-PET add information to EUS and CT in the initial

- management of esophageal cancer? A prospective single center study. Am J Gastroenterol 2008;103:570-4.
83. Grogan E, **Jones DR**. VATS lobectomy is better than open thoracotomy: What is the evidence for short-term outcomes? Thorac Surg Clin 2008;18:249-58.
84. Taylor MD, **Jones DR**. Genetic markers of mediastinal diseases. Thorac Surg Clin 2009;19:17-27.
85. Cai J, Read PW, Lerner JM, **Jones DR**, Benedict SH, Sheng K. Reproducibility of interfraction lung motion probability distribution function using dynamic MRI: statistical analysis. Int J Radiat Oncol Biol Phys 2008;72:1228-35..
86. Grogan EL, Stuckenborg GJ, Nagji AS, Simmons W, Kozower BD, **Jones DR**, Daniel TM. Radiotracer-guided thoracoscopic resection (RGTR) is a cost-effective technique for the evaluation of sub-centimeter pulmonary nodules. Ann Thorac Surg 2008;86:934-40.
87. Kozower BD, Stukenborg GJ, Lau CL, **Jones DR**. Measuring the quality of surgical outcomes in general thoracic surgery: should surgical volume be used to direct patient referrals? Ann Thorac Surg 2008;86:1405-8.
88. **Jones DR**. Technique of superior vena cava resection for lung carcinomas. Op Tech Thorac Cardiovasc Surg 2008;13:274-82.
89. McKay G, Arlet V, Kern JA, Lau CL, **Jones DR**, Kozower BD. A bi-lobed thoracic outlet mass: options for resection. J Thorac Cardiovasc Surg 2009;137:245-7.
90. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, **Jones DR**. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg 2009;35:699-705.
91. Taylor MD, Smith PW, Brix WK, Wick WR, Theodosakis N, Swenson BJ, Kozower BD, Lau CL, **Jones DR**. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:43-8.
92. Ailawadi G, Lau CL, Fedoruk LM, Smith PW, Kuhn C, Kozower BD, Kern JA, Peeler BB, Kron IL, **Jones DR**. Does reperfusion injury still cause significant mortality after lung transplantation? J Thorac Cardiovasc Surg 2009;137:688-94.
93. Smith PW, Liu Y, Siefert SA, Petroni GR, Moskaluk CA, **Jones DR**. Breast Cancer Metastasis Suppressor 1 (*BRMS1*) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Letters 2009;276:196-203.
94. Bellizzi AM, Woodford RL, **Jones DR**, Kozower BD, Stelow EB. Basaloid squamous cell carcinoma of the esophagus: assessment for high-risk human papillomavirus and related molecular markers. Am J Surg Path 2009;33:1608-14.

95. Swee W, Housseini AM, Angle JF, **Jones DR**, Daniel TM, Turba UC, Abdel-Gawad EA, Hagspiel KD. Preoperative embolization of Castleman's disease using microspheres. Ann Thorac Surg 2009;88:1999-2010.
96. Walters DM, Dunnington GH, Dustin SM, Frierson HF, Peeler BD, Kozower BD, Ailwadi G, **Jones DR**, Lau CL. Rosai-Dorfman disease manifesting as a pulmonary artery mass causing right heart failure, a case report and review of the literature. Ann Thorac Surg 2010;89:300-2.
97. Hennessey SA, Grogan EL, Harthun NL, **Jones DR**, Kozower BD, Ailawadi G, Lau CL. Transplant pneumonectomy in a patient with an acutely thrombosed allograft. Ann Thorac Surg 2010;89:975-7.
98. **Jones DR**, Taylor MD, Petroni GR, Shu J, Burks SG, Daniel TM, Gillenwater HH. Phase I trial of intrapleural docetaxel administered via an implantable catheter in subjects with a malignant pleural effusion. J Thorac Oncol 2010;5:75-81.
99. Kozower BD, Ailawadi G, **Jones DR**, Lau CL, Pates RD, Kron IL, Stukenborg GJ. Does the university health system consortium risk adjusted mortality model for adult cardiac surgery have an unfair advantage over the society of thoracic surgeons model? J Am Coll Surg 2009;209:551-6.
100. Kozower BD, Lau CL, Phillips JV, Burks SG, **Jones DR**, Stukenborg GJ. A thoracic surgeon-directed tobacco cessation intervention. Ann Thorac Surg 2010;89:926-30.
101. Hennessey SA, Hranjec T, Swenson BR, Kozower BD, **Jones DR**, Ailawadi G, Kron IL, Lau CL. Donor factors are associated with bronchiolitis obliterans syndrome after lung transplantation. Ann Thorac Surg 2010;89:1555-62.
102. Taylor MD, Liu Y, Nagji AS, Theodosakis N, **Jones DR**. Combined proteasome and histone deacetylase inhibition upregulates e-cadherin metastasis suppressor gene expression and attenuates epithelial-mesenchymal transition in esophageal cancer. J Thorac Cardiovasc Surg 2010;139:1224-32.
103. Ailawadi G, Nagji AS, **Jones DR**. The legends behind cardiothoracic surgical instruments. Ann Thorac Surg 2010;89:1693-700.
104. Dunlap NE, Lerner JM, Read PW, Kozower BD, Lau CL, Sheng K, **Jones DR**. Size matters: A comparison of T1 and T2 peripheral non-small cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010;140:583-9.
105. Nagji AS, Hranjec T, Swenson BR, Kern JA, Bergin JD, **Jones DR**, Kron IL, Lau CL, Ailawadi G. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg 2010;90:168-75.
106. Scott WJ, Allen MS, Darling G, Meyers BF, Decker PA, Putnam JB, McKenna RW, Landreneau RJ, **Jones DR**, Incelet RI, Malthaner RA. Perioperative outcomes of video-assisted

- (VATS) for lung cancer compared to open thoracotomy: An analysis of data from the American College of Surgeons Oncology Group (ACOSOG) Z0030 clinical trial. J Thorac Cardiovasc Surg 2010;139:976-83.
107. Kozower BD, Sheng S, O'Brien SM, Liptay MJ, Lau CL, **Jones DR**, Shahian DM, Wright CD. STS database risk models: Predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg 2010;90:875-83.
108. LaPar DJ, Bhamidipati CM, Mery CM, Stukenborg GJ, **Jones DR**, Schirmer BD, Kron IL, Ailawadi G. Primary payer status affects mortality for major surgical operations. Ann Surg 2010;252:544-50.
109. Nagji AS, Liu Y, Stelow EB, Stukenborg GJ, **Jones DR**. *BRMS1* transcriptional repression correlates with CpG island methylation and advanced pathologic stage in non-small cell lung cancer. J Pathol 2010;221:229-37.
110. Evangelista AM, Rao AR, Filo AR, Marozkina NV, Doctor A, **Jones DR**, Gaston B, Guilford WH. Direct regulation of striated muscle myosins by nitric oxide and endogenous nitrosothiols. PLOS One 2010;5:e11209.
111. Liu Y, Nagji AS, **Jones DR**. The complex relationship between NF- $\kappa$ B and p53: Implications for lung cancer. Cell Science 2010.
112. Stelow EB, Shami VM, Moskaluk CA, Burns KG, Legallo RD, **Jones DR**. Esophageal myofibroblastic tumor sampled by EUS-FNA. Gastrointest Endosc 2010;72:209-10.
113. Nagji AS, Cho SH, Liu Y, Lee JK, **Jones DR**. Multi-gene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther 2010;9:2834-43.
114. Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers BF, DiPetrillo TA, Heron D, **Jones DR**, Daly BDT, Putnam JB. The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea in High-risk Operable Patients; Preliminary results from the ACOSOG Z4032 Trial. J Thorac Cardiovasc Surg 2011;142:554-62.
115. Isbell JM, Deppen S, Putnam JB, Nesbitt JC, Lambright ES, Dawes A, Massion PP, Speroff T, **Jones DR**, Grogan EL. Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation? Ann Thorac Surg 2011;91:227-33.
116. Darling GE, Allen MS, Decker PA, Ballman K, Putnam JB, Malthaner RA, Inculet RI, **Jones DR**, McKenna RJ, Landreneau RJ. Number of lymph nodes harvested from a mediastinal lymphadenectomy: Results of the randomized, prospective ACOSOG Z0030 trial. Chest 2011;139:1124-9.

117. LaPar DJ, Nagji A, Bhamidipati CM, Kozower BD, Lau CL, Ailawadi A, **Jones DR**. Seasonal variation influences outcomes following lung cancer resections. Eur J Cardiothorac Surg 2011;40:83-90.
118. Hennessy SA, Hranjec T, Kozower BD, **Jones DR**, Kron IL, Lau CL. Postoperative dialysis is a highly fatal complication in lung transplant recipients. J Surg Res 2012 (submitted).
119. Dettner FC, Frencher Jr SK, Gould MK, Bach P, **Jones DR**. A model for regional organization of thoracic surgical care. Chest 2011 (submitted).
120. Enfield K, Truwit JD, White C, **Jones DR**. Bilateral intrapulmonary sequestrations. Am J Resp Crit Care Med 2011 (in press).
121. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA., Inculet RI, **Jones DR**, McKenna RJ, Rodney J, Landreneau RJ, Rusch VW, Putnam JB. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: Results of the ACOSOG Z0030 trial. J Thorac Cardiovasc Surg 2011;141:662-70.
122. Emamina A, Hennessy SA, Hranjec T, LaPar DJ, Kozower BD, **Jones DR**, Kron IL, Lau CL. Bronchiolitis obliterans syndrome occurs earlier in the post lung allocation score era. J Thorac Cardiovasc Surg 2011;141:1278-82.
123. Nagji AS, Stukenborg GJ, Peluso MR, Taylor MD, Kozower BD, Lau CL, **Jones DR**. Predictors of hospital discharge to extended care facility following major general thoracic surgery. Arch Surg 2012 (submitted).
124. LaPar DJ, Bhamidipati CM, Kozower BD, **Jones DR**, Kron IL, Ailawadi G, Lau CL. Gender, race, and socioeconomic status affects outcomes following lung cancer resections in the United States. Ann Thorac Surg 2011;92:434-9.
125. Hennessy SA, Hranjec T, Emamina A, LaPar DJ, Kozower BD, **Jones DR**, Kron IL, Lau CL. Geographic distance between donor and recipient does not influence bronchiolitis obliterans syndrome after lung transplantation. Ann Thorac Surg 2011;92:1847-53.
126. LaPar DJ, Stukenborg GS, Lau CL, **Jones DR**, Kozower BD. Does preoperative pulmonary function impact long-term survival following lung cancer resection? Ann Thorac Surg 2011 (submitted).
127. Zhao Y, Turlington M, LaPar DJ, **Jones DR**, Harris DA, Kron IL, Pu L, Lau CL. Characterization of novel synthesized small molecular compounds against non-small cell lung cancer. Ann Thorac Surg 2011;92:1031-7.
128. Marozkina NV, Wei C, Yemen S, Wallrabe H, Nagji AS, Liu L, Morozkina T, **Jones DR**, Gaston B. S-nitrosoglutathione reductase in human lung cancer. Am J Resp Cell Mol Biol 2012;46:63-70.



129. Blank RS, Hucklenbruch C, Gurka KK, Scalzo DC, Wang XQ, **Jones DR**, Tanner SR, Jaeger JM. Intraoperative factors and the risk of respiratory complications after pneumonectomy. Ann Thorac Surg 2011;92:1188-94.
130. Rusch VW, Hawes D , Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, **Jones DR**, Malthaner RA, Cohen RG, Ballman K, Putnam JB, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small cell lung cancer: Report of the ACOSOG Z0040 trial. J Clin Oncol 2011;29:4313-9.
131. Dunlap N, McIntosh A, Sheng K, Yang W, Turner B, Shoushtari A, Sheehan J, **Jones DR** , Lu W, Ruchala K, Olivera G, Parnell D, Lerner JL, Benedict SH, Read PW.. Helical tomotherapy-based STAT SBRT: dosimetric evaluation for a real time SBRT treatment planning and delivery program. Med Dosimetry 2011;35:312-9.
132. Zhao Y, Sharma AK, LaPar DJ, Kron IL, Liu Y, **Jones DR**, Laubach VE, Lau CL. Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation. J Appl Physiol-Lung 2011;300:L718-29.
133. **Jones DR**, Mack MJ, Patterson GA, Cohn LH. A positive return on investment: Research funding by the Thoracic Surgery Foundation for Research and Education (TSFRE). J Thorac Cardiovasc Surg 2011;141:1103-6.
134. Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron D, **Jones DR**, Daly BDT, Starnes SL, Tan A, Putnam JB. Thirty and ninety day outcomes after sublobar resection for non-small cell lung cancer: Results from a multicenter phase III study. J Thorac Cardiovasc Surg 2011;142:1143-51.
135. Stone ML, Kilic A, **Jones DR**, Lau CL, Kozower BD. A diagnostic consideration for all ages: pseudoachalasia in a 22 year old. Ann Thorac Surg 2012;93:e11-2.
136. Isbell JM, **Jones DR**. Parenchymal-sparing lung resections: Technique of sleeve resections. Op Tech Cardiovasc Thorac Surg 2011;16:215-25.
137. Panneerdoss S, Mandal A, SuryavathiV, Liu Y, Shetty J, Chertihin O, Bruns DE, **Jones DR**, Frierson HF, Jameson MJ, Herr JC. Expression of multiple CABYR splice variants and proteins in lung tumors. Int J Cancer 2012 (submitted).
138. Taylor MD, Nagji AS, Petroni GR, Theodosakis N, Kozower BD, Lau CL, **Jones DR**. What are the predictors of recurrence following an R0 resection for non-small cell lung cancer? Ann Thorac Surg 2012 (in press).
139. Bhamidipati CM, Stukenborg GS, Thomas CJ, Lau CL, Kozower BD, **Jones DR**. Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg 2012 (in press).

140. Enfield KB, Floyd S, Barker B, Tester R, Weder M, Sifri C, **Jones DR**, Lau CL. Survival following lung transplant for coal worker's pneumoconiosis. J Heart Lung Transpl 2012 (submitted).
141. LaPar D, Bhamidipathi CM, Lau CL, **Jones DR**, Kozower BD. The society of thoracic surgeon's general thoracic surgery database: establishing generalizability to national lung cancer resection outcomes. Ann Thorac Surg 2012 (submitted).
142. Kozower BD, Lerner JM, Detterbeck FC, **Jones DR**. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2012 (in press).
143. **Jones DR**, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, et al. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small cell lung cancer. J Thorac Oncol 2012 (submitted).
144. Liu Y, Mayo MW, Nagji AS, Smith PW, Ramsey CS, Li D, **Jones DR**. Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene *BRMS1*. Oncogene 2012;31:1143-54.
145. Muttikkal, TE, Shami V, **Jones DR**, Rehm P. Fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) demonstration of carcinoma arising in an epiphrenic diverticulum. Dis Esophagus 2012 (submitted).
146. LaPar DJ, Kron IL, **Jones DR**, Stukenborg GJ, Kozower BD. Hospital procedure volume should not be used as a measure of surgical quality. Ann Surg 2012 (submitted).
147. Fibla JJ, Cassivi SD, Brunelli A, Decker PA, Allen MS, Darling GE, Landreneau RJ, McKenna RJ, **Jones DR**, Putnam JB. Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer. Eur Respir J 2012 (submitted).
148. Liu Y, Mayo MW, Nagji AS, Allred EH, Shock LS, Xiao A, Stelow EB, **Jones DR**. BRMS1 suppresses lung cancer metastases via a novel E3 ligase function on the histone acetyltransferase p300. EMBO Journal 2012 (submitted).
149. Bhamidipati CO, Stukenborg GJ, Ailawadi G, Lau CL, Kozower BD, **Jones DR**. Pulmonary resections performed at thoracic surgery teaching hospitals have superior outcomes. J Thorac Cardiovasc Surg 2012 (submitted).
150. Hu Y, Ezekian B, **Jones DR**, Lau CL, Burks S, Schirmer B, Kozower BD. Long term patient satisfaction and medication dependence after antireflux surgery. Ann Thorac Surg 2012 (submitted).
151. Kent M, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, **Jones DR**, Starnes SL, Tan A, Putnam JB, Meyers B, Daly BDT, Fernando HC. Segmentectomy is superior to wedge resection for non-small cell lung cancer in high-risk operable patients. Ann Thorac Surg 2012 (submitted).

152. Yount KW, Patel NA, Harnain CM, Srikanth S, Irwin W, Millsap ET, Teuscher E, Kozower BD, **Jones DR**, Kron IL, Weiss EN, Lau CL. Use of lean thinking and Kaizen to analyze thoracic surgery operating room efficiency at a tertiary care academic medical center. Ann Thorac Surg 2012 (submitted).

Book Chapters:

1. Graeber GM, **Jones DR**, Pairolero PC. Primary neoplasms. In: Pearson FG, Deslauries J, Ginsberg RJ, Hiebert CA, McNeally MF, and Urschel HG Jr. (eds). Thoracic Surgery. New York: Churchill Livingstone, 1995.
2. **Jones DR**, Graeber GM. Cysts and duplications in adults. In: Pearson FG, Deslauries J, Ginsberg RJ, Hiebert CA, McNeally MF, and Urschel HG Jr. (eds). Thoracic Surgery. New York: Churchill Livingstone, 1995.
3. **Jones DR**, Graeber GM. Posterior mediastinal tumors. In: Martini N, Aisner J, Arriagada R, Green MR, and Perry MC (eds). Comprehensive Textbook of Thoracic Oncology. Baltimore: Williams & Wilkins, 1996.
4. Detterbeck FC, **Jones DR**, Parker, LA. Intrathoracic staging In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
5. Detterbeck FC, **Jones DR**, Molina PL. Extrathoracic staging. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
6. **Jones DR**, Detterbeck FC. Surgery for stage I. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
7. Detterbeck FC, **Jones DR**, Rosenman JG. Pancoast tumors. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
8. Detterbeck FC, **Jones DR**. Surgery for IIIa(N2) disease. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
9. Detterbeck FC, **Jones DR**. Surgery alone for IIIb disease. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
10. Detterbeck FC, **Jones DR**, Funkhouser WK. Bronchioloalveolar carcinoma. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.

11. **Jones DR**, Detterbeck FC, Morris D. Tracheal cancer. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
12. Detterbeck FC, **Jones DR**, Morris D. Palliation. In: Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. Detterbeck FC, Rivera MP, Rosenman JG, Socinski MA (eds). NY: WB Saunders, 2001.
13. Detterbeck FC, **Jones DR**, Funkhouser WK. Multiple primary lung cancers. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Clinician. NY: WB Saunders, 2001.
14. Binns OAR, **Jones DR**. Thoracoscopy for trauma. Video-Assisted Thoracic Surgery (VATS). Demmy TL ed. Landes Bioscience, Georgetown, TX, 2001.
15. Buchanan SA, **Jones DR**. Management of chest wall trauma. Current Surgical Therapy. Cameron JL ed., Mosby, 2001.
16. Graeber GM, **Jones DR**, Pairolero PC. Primary neoplasms. In: Pearson FG, Deslauries J, Ginsberg RJ, Hiebert CA, McNeally MF, and Urschel HG Jr. (eds). Thoracic Surgery. New York: Churchill Livingstone, 2001.
17. **Jones DR**. Anterior Mediastinal Masses. Current Therapy in Thoracic and Cardiovascular Surgery. Yang S. and Cameron D., eds. Harcourt Health Sciences, Philadelphia, PA, 2004.
18. Mayo MW and **Jones DR**. Dynamic regulation of NF- $\kappa$ B transcriptional activity via recruitment of co-activator and co-repressor complexes. Mechanisms of signal transduction and inducible gene expression. Research Signpost Publisher. Note: This is an invited book chapter. 2004.
19. **Jones DR**, Rundall BK. Atelectasis. Conn's Current Therapy. Rakel RE and Bope ET, eds. WB Saunders Co. 2005.
20. Smith PW, **Jones DR**. Biology and Epidemiology of Lung Cancer. In: Pearson, Patterson GA, Cooper, Deslauriers J, Lerut T, Luketich J, and Rice TW. Pearson's Textbook of Thoracic-Esophageal Surgery. New York: Churchill Livingstone, 2007.
21. Graeber GM, **Jones DR**, Pairolero PC. Primary neoplasms. In: Pearson, Patterson GA, Cooper, Deslauriers J, Lerut T, Luketich J, and Rice TW. Pearson's Textbook of Thoracic-Esophageal Surgery. New York: Churchill Livingstone, 2007.
22. **Jones DR**. Chest wall resection and reconstruction. In: Sugarbaker DS, Bueno R, Zellos L (eds.). Adult Chest Surgery: Concepts and Procedures. McCraw-Hill, Inc., 2009.
23. Philips K, **Jones DR**, Lau CL. Pulmonary complications of cystic fibrosis. Shield's General Thoracic Surgery, 2008.

24. Nagji AS, **Jones DR**. Other primary tumors of the lung. In: Sellke FW, del Nido PJ, Swanson SJ, (eds.). *Surgery of the Chest*, 8<sup>th</sup> edition Philadelphia, PA: Elsevier, 2010.
25. Bhamidipati CM, **Jones DR**. Screening for lung cancer. In: Franco KL and Thourani VH (eds.) *Cardiothoracic Surgery Review*, Philadelphia PA: Lippincott, Williams and Wilkins, 2011.
26. Nagji AS, **Jones DR**. Solitary pulmonary nodule. In: Franco KL and Thourani VH (eds.) *Cardiothoracic Surgery Review*, Philadelphia PA: Lippincott, Williams and Wilkins, 2011.
27. Bhamidipati CM, **Jones DR**. Chylothorax. In: Franco KL and Thourani VH (eds.) *Cardiothoracic Surgery Review*, Philadelphia PA: Lippincott, Williams and Wilkins, 2011.
28. Taylor MD, **Jones DR**. Techniques to remove and replace the esophagus. In: Franco KL and Thourani VH (eds.) *Cardiothoracic Surgery Review*, Philadelphia PA: Lippincott, Williams and Wilkins, 2011.
29. Nagji AS, **Jones DR**. The biology of lung cancer. *European Society of Thoracic Surgeons Textbook on Thoracic Surgery*. 2011.
30. Fernandez LG, Isbell JM, **Jones DR**, Laubach VE. Compensatory lung growth after pneumonectomy. *Compensatory Lung Growth After Pneumonectomy, Topics in Thoracic Surgery*, Paulo F. Guerreiro Cardoso (Ed.), ISBN: 978-953-51-0010-2, InTech, Available from: <http://www.intechopen.com/articles/show/title/compensatory-lung-growth-after-pneumonectomy>. 2012
31. **Jones DR**. Chest wall resection and reconstruction. In: Sugarbaker DS, Bueno R, Zellos L (eds.). *Adult Chest Surgery: Concepts and Procedures*. McCraw-Hill, Inc., 2012.

#### Invited Commentaries

1. **Jones DR**. Iyoda A, Hiroshima K, Baba M, Fujisawa T, Yusa T, Ohwada H. Expression of vascular endothelial growth factor in thoracic sarcomas. *Ann Thorac Surg* 2001;71:1935-9.
2. **Jones DR**. Reflections of a young surgeon. *Bulletin: American College of Surgeons*. 2002;87:43-4.
3. **Jones DR**. Briel JW. Tamhankar AP. Hagen JA. DeMeester SR. Johansson J. Choustoulakis E. Peters JH. Bremner CG. DeMeester TR. Prevalence and risk factors for ischemia, leak, and stricture of esophageal anastomosis: gastric pull-up versus colon interposition. *J Am Coll Surg* 2004;198:536-41.
4. **Jones DR**. Introduction. *Molecular Biology of Lung Cancer*. *Semin Thorac Cardiovasc Surg*. 2004;16:2.

5. **Jones DR.** Shimamoto A, Shomura S, Tarakawa T, Takao M, Shimpo H. Toll-Like Receptor 4 Mediates Lung Ischemia-Reperfusion Injury. Ann Thorac Surg. 2006;82:2023.
6. **Jones DR.** Brunelli A, Pompili C, Refai, Xiume F, Salati M, Sabbatini A. Predicted versus observed peak oxygen consumption following major pulmonary resection. Ann Thorac Surg 2012 (in press).

#### Abstracts

1. **Jones DR,** Abbott AE Jr, Hill RC. Effect of CaCl<sub>2</sub> in the reperfused isolated working rat heart using verapamil based cardioplegia. WV St Med J 1989; 85:536.
2. **Jones DR,** Abbott AE Jr., Hill RC, Beamer KC, Gustafson RA, Murray GF. Amelioration of ventricular dysfunction associated with hypercalcemic reperfusion using verapamil cardioplegia. Chest 1993; 104:35A.
3. **Jones DR,** Kalantarian B, Wearden PD, Femovich DA, Warden HE, Hill RC, Graeber GM. Diagnosis and management of Boerhaave's Syndrome. Chest 1994; 106:90S.
4. Kalantarian B, Graeber GM, **Jones DR,** Chailko DM, Murray GF. Determination of the optimal length and diameter of intra-aortic balloon catheter. Chest 1994; 106:132S.
5. Lucas C, Mill M, Jones D, Lucas W, Yim P, Ha B, Wilcox BR. A lamb model of the Fontan circulation. J Cardiovasc Diag Proc 1996; 12:119.
6. **Jones DR,** Becker RM, Lemasters JJ, Egan TM. Is pulmonary microvascular integrity maintained after death? Chest 1996; 110:221S.
7. Bernard SA, Poole ME, Socinski MA, Detterbeck FC, Egan TM, **Jones DR,** et al. Paclitaxel (T) combined with 5-fluorouracil (FU) and cisplatin (P) concomitant with radiotherapy (RT) in locally advanced or metastatic esophageal cancer: preliminary report of phase I/II trials. Proc Am Soc Clin Oncol 1998;17:286a.
8. Bleiweis MS, **Jones DR,** Hoffmann SC, Becker RM, Egan TM. Reduced ischemia-reperfusion injury (IRI) with rolipram in rat cadaver lung donors: effect of cAMP? Chest 1998;114:284S.
9. **Jones DR,** Schottelius AJG, Madrid LV, Broad RM, Baldwin AS, Mayo MW. Chemotherapy-induced NF- $\kappa$ B activation in NSCLC occurs through an IKK-independent mechanism. Proc Am Assn Cancer Res 2001;42:254.
10. De Lange EE, Stoler MH, Truwit JD, Daniel TM, **Jones DR,** Altes T, Mugler JP, Brookeman JR. Hyperpolarized helium-3 MR imaging, computed tomography and spirometry, assessments in patients with emphysema: comparison with histology. Proc Intl Soc Mag Reson Med 2001;9:1.

11. De Lange EE, **Jones DR**, Altes TA, Daniel TM, Salerno MS, Brookeman JR, Mugler JP. Bronchiolitis obliterans following lung transplantation: evaluation with hyperpolarized helium-3-MR imaging. Proc Intl Soc Mag Reson Med 2002 (in press).
12. Denlinger CE, Broad RM, Reilly ET, Mayo MW, **Jones DR**. Inhibition of histone deacetylation and NF- $\kappa$ B activation sensitizes NSCLC to undergo apoptosis. J Am Coll Surg 2002;195:S27.
13. Aldalaan AM, **Jones DR**, Robbins MK, Matsumoto AH, Tribble CG, Kron IL. Bronchial anastomotic stenoses following lung transplantation: incidence and treatment. Chest 2002;122:109S.
14. Robbins MK, Ryan BJ, **Jones DR**. Lung transplantation for end-stage sarcoidosis; an effective treatment strategy. Chest 2002;122:79S.
15. Denlinger CE, Mayo MW, **Jones DR**. Combination proteasome inhibition and gemcitabine Chemosensitizes NSCLC to apoptosis by inhibition of NF- $\kappa$ B. Proc Am Assn Cancer Res 2003;44:1058.
16. Denlinger CE, Mayo MW, **Jones DR**. Akt is required for histone deacetylase inhibitor-induced activation of NF- $\kappa$ B. Proc Am Assn Cancer Res 2003;44:633.
17. Denlinger CE, Mayo MW, **Jones DR**. Proteasome inhibition sensitizes NSCLC to generation of reactive oxygen species and cell death. Lung Cancer 2003;41 (Suppl):S177.
18. Denlinger CE, Mayo MW, **Jones DR**. Pharmacological NF-kappa B inhibition sensitizes gemcitabine-resistant NSCLC to apoptosis. J Am Coll Surg 2003;197:S29-30.
19. Rundall BK, Denlinger CE, **Jones DR**. Efficacy of histone deacetylase inhibitors in NSCLC is attenuated by NF- $\kappa$ B acetylation. J Am Coll Surg 2004; 199:S31.
20. Liu Y, Smith PW, **Jones DR**. Breast cancer metastasis suppressor-1 (BRMS1) modulates NF-kappa B-dependent transcription via acetylation of RelA/p65. Proc Am Assn Cancer Res 2006;1012.
21. Mcdonough P, **Jones DR**, Shen RK, Northup PG, Hernandez AJ, Kahaleh M, White GE, Shami VM. Does positron emission tomography add information to endoscopic ultrasound sonography and CT in the management of esophageal cancer? A prospective single center study, Am J Gastroenterol 2006; 101(9); AB49.
22. Romney DA, Baisden JM, **Jones DR**, Sheng K, Read PW, Larner JM. Helical tomotherapy SBRT for lung lesions: recommendations for potential candidates based on tumor size and location. ASTRO 2006.

23. Brix WK, Ormsby WD, Wick MR, **Jones DR**, Stelow EB. The histologic assessment of pulmonary non-small cell carcinoma after neoadjuvant therapy. Mod Pathol 2006; 20:318A
24. McDonough PB, Galysh R, **Jones DR**, Shen RK, Northup PG, Hernandez AJ, White GE, Kahaleh M, Shami VM. Does positron emission tomography add information to endoscopic ultrasound sonography and CT in the management of esophageal cancer? Gastrointest Endosc 2007; 65(5); A136.
25. Allen MS, Darling GE, Decker PA, Putnam JB, Malthaner RA, Inculet RI, **Jones DR**, McKenna RJ, Landreneau RJ. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial. ASCO 2007.
26. Taylor MD, Nagli AS, Kozower BD, Daniel TM, **Jones DR**. Intermediate results of primary and redo transthoracic repairs of paraesophageal hernias. Interact Cardiovasc Thorac Surg 2007;6:S209.
27. Smith PW, Brix WK, Atkins KA, Taylor M, Theodosakis N, Kozower BD, **Jones DR**, Wick MR. Glucose Transporter-1 (GLUT1) expression and PET-CT-SUVmax in esophageal carcinomas. Mod Pathol 2008.136A.
28. Brix WK, Ormsby WD, Smith PW, Theodosakis N, **Jones DR**, Wick MR, Conaway MA, Stelow EB. Response to neoadjuvant therapy and survival with pulmonary non-small cell carcinoma. Mod Pathol 2008;337A.
29. Liu Y, Smith PW, Taylor MD, **Jones DR**. BRMS1 transcription is repressed by DNA methylation and functions as both a metastasis and a tumor suppressor gene in non-small cell lung cancer. Proc Am Assn Cancer Res 2008;326.
30. Hennessy SA, Grogan EL, Harthun NL, **Jones DR**, Kozower BD, Lau CL. Symptomatic pulmonary emboli in lung transplant recipients. International Society of Heart Lung Transplantation. Paris, France 2009.
31. Nagji A, Cho SH, Liu Y, Lee JK, **Jones DR**. Use of the “coexpression extrapolation” algorithm to identify tumor biomarkers that predict drug sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Proc Am Assn Cancer Res 2010.
32. Fibla JJ, Cassivi SD, Decker PA, Allen MS, Darling GE, Landreneau RJ, McKenna RJ, **Jones DR**, Inculet RI, Putnam JB. Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). Amer Soc Clin Oncol 2010.
33. Nagji AS, Liu Y, Stelow EB, Stukenborg GJ, **Jones DR**. *BRMS1* promoter methylation correlates with decreased expression of BRMS1 in non-small cell lung cancer. Proc Am Assn Cancer Res 2010.



34. Liu Y, Nagji AS, Taylor MD, **Jones DR**. Proteasome inhibitor bortezomib induces E-cadherin re-expression through inhibiting NF- $\kappa$ B mediated DNA methylation in esophageal cancer. Proc Am Assn Cancer Res 2010.
35. Hennessy SA, Hranjec T, Kozower BD, **Jones DR**, Lau CL. Postoperative dialysis is a highly fatal complication after lung transplantation. J Heart Lung Transpl 2010;S80.
36. Rehm PK, Person LD, **Jones DR**. Nuclear Medicine Case of the Day. Radiological Society of North America Web site. 2010 <http://www.rsna.org/education>.
37. LaPar DJ, Nagji AS, Bhamidipati CM, Kozower BD, Lau CL, Ailawadi A, **Jones DR**. Season variation influences outcomes following lung cancer resections. Interact CardioVasc Thorac Surg 2010;11:S4.
38. Hucklenbruch C, Gottschalk A, Scalzo DC, Wang XQ, Gurka KK, **Jones DR**, Blank RS. Risk factors for the development of primary graft dysfunction after lung transplantation. Anästh Intensivmed 2010;51:S739.
39. Hucklenbruch C, Gottschalk A, Scalzo DC, Gurka KK, **Jones DR**, Jaeger JM, Blank RS. Impact of anesthetic factors on the risk of respiratory complications after pneumonectomy. Anästh Intensivmed 2010;51:S739.
40. Woodford R, Nagji A, **Jones DR**, Stelow EB. Lung carcinomas in young patients: A clinicopathologic and immunohistochemical assessment of 140 cases. Mod Pathol 2011;24: 428A.
41. Jeffus S, Nagji A, Kozower B, **Jones DR**, Stelow EB. Assessing the pleura and other objective and routine findings predicting outcome with stage I non-small cell lung carcinoma. Mod Pathol 2011; 24: 413A.
42. Harpole D, Ballman KV, Oberg AL, Whiteley G, Cerfolio R, Keenan R, **Jones DR**, D'Amico TA, Shrager J, Putnam JB. Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. American Society of Clinical Oncology, J Clin Oncol 2011;29:S7003.

### **Invited Lectures and Presentations**

#### **West Virginia University and University of North Carolina at Chapel Hill**

1. Abbott AE Jr, Hill RC, **Jones DR**, Beamer KC, Gustafson RA, Murray GF. Effects of calcium chloride during reperfusion in hearts arrested with verapamil based cardioplegia. Society of University Surgeons, Residents Forum, Los Angeles, CA, February 1990.
2. **Jones DR**, Vaughan RA, Timberlake GA. Current methods of diagnosis and management of pancreatic pseudocysts. Southern Medical Association, Nashville, TN, October 1990.
3. **Jones DR**. Cardioplegia solutions and their use. Department of Pharmacology, Ruby Memorial Hospital, Morgantown, WV, November 1991.

4. **Jones DR.** Giant benign mucinous cystadenoma of the ovary: Case report and literature review. Poster presentation, Southeastern Surgical Congress, New Orleans, LA, April 1991.
5. **Jones DR.** Effect of CaCl<sub>2</sub> in the reperfused isolated working rat heart using verapamil-based cardioplegia. West Virginia Chapter of the American College of Surgeons, White Sulphur Springs, WV, April 1991.
6. **Jones DR.** Diverticular disease. Department of Surgery Grand Rounds, West Virginia University School of Medicine, Morgantown, WV, June 1991.
7. **Jones DR.** Myocardial protection and cardioplegia solutions. School of Pharmacy, West Virginia University, Morgantown, WV, February 1992.
8. **Jones DR.** Surgical nutrition. Department of Surgery Grand Rounds, West Virginia University School of Medicine, Morgantown, WV, June 1992.
9. **Jones DR,** Graeber GM, Tanguilig GG, Hobbs G, Murray GF. The effects of insufflation on hemodynamics during thoracoscopy. The Society of Thoracic Surgeons, San Antonio, TX, January 1993.
10. **Jones DR,** Cortes V. Complex multi-system shotgun injuries. Alleghany General Hospital Trauma Tactics. Aspen at Snowmass, CO, March 1993.
11. **Jones DR.** Principles of intraoperative myocardial protection. School of Pharmacy, West Virginia University, Morgantown, WV, March 1993.
12. Keeting PE, **Jones DR,** Pivrotto LA, Graeber GM. Diabetic human osteoblast-like cell growth and differentiation. The American Society for Bone and Mineral Research, Tampa, FL, September 1993.
13. Nelson MG, **Jones DR,** Wearden PD, Graeber GM. Clinical manifestations of the Marfan syndrome. Poster presentation, American College of Surgeons, San Francisco, CA, October 1993.
14. Wearden PD, **Jones DR,** Vasilakis A. Acute diverticulitis in patients less than age 40: Analysis of 411 patients. Poster presentation, American College of Surgeons, San Francisco, CA, October 1993.
15. **Jones DR,** Abbott AE Jr., Hill RC, Beamer KC, Gustafson RA, Murray GF. Amelioration of ventricular dysfunction associated with hypercalcemic reperfusion using verapamil cardioplegia. Poster presentation, American College of Chest Physicians, Orlando, FL, October 1993.
16. **Jones DR.** Current therapy of Barrett's esophagus. Department of Surgery Grand Rounds, West Virginia University School of Medicine, Morgantown, WV, July 1993.

17. **Jones DR.** Diaphragm injuries: A ten-year experience at a rural university hospital. Trauma Manuscript Competition, West Virginia Chapter of the American College of Surgeons, Morgantown, WV, September 1993.
18. **Jones DR,** Davidson AG, Quinlan DC, Summers CL, Murray GF. The potential application of p53 as an intermediate biomarker in Barrett's esophagus. Southern Thoracic Surgical Association, Panama City Beach, FL, November 1993.
19. Hill RC, **Jones DR,** Vasilakis A, Hollingsed M, Gustafson RA, Graeber GM, Murray GF. Safe utilization of heparin coated bypass circuits incorporating a pump-oxygenator. Southern Thoracic Surgical Association, Panama City Beach, FL, November 1993.
20. **Jones DR,** Nelson MC, Kizer JD, Timberlake GA. Diaphragmatic injuries: A ten-year experience at a rural university hospital. Regional Manuscript Competition, American College of Surgeons, Norfolk, VA, December 1993.
21. Nelson MG, **Jones DR,** Timberlake GA, Kizer JD. Diaphragmatic injuries: A ten-year experience at a rural university hospital. International Surgical Week, 35th World Congress of the International Society of Surgery, Hong Kong, August 1993.
22. **Jones DR.** Diagnosis and management of Barrett's esophagus. Department of Surgery Grand Rounds, West Virginia University, Charleston Division, Charleston, WV, December 1993.
23. **Jones DR,** Davidson AG, Summers CL, Quinlan DC, Murray GF, Warden HE. Lack of significance of p53 and c-erbB-2 as independent prognostic indicators in esophageal carcinoma. Society of University Surgeons, Resident's Forum, Jackson, MS, February 1994.
24. **Jones DR.** Neurogenic tumors of the posterior mediastinum. Department of Surgery Grand Rounds, West Virginia University School of Medicine, July 1994.
25. **Jones DR,** Kalantarian B, Wearden PD, Femovich DA, Warden HE, Hill RC, Graeber GM. Diagnosis of management of Boerhaave's syndrome. Poster presentation, American College of Chest Physicians, New Orleans, LA, October 1994.
26. Kalantarian B, Graeber GM, **Jones DR,** Chilko DM, Murray GF. Determination of the optimal length and diameter of intra-aortic balloon catheter. Poster presentation, American College of Chest Physicians, New Orleans, LA, October 1994.
27. **Jones DR,** Warden HE, Murray GF, Hill RC, Gustafson RA, Graeber GM, Vasilakis A. Biatrial approach to cardiac myxomas: A 30 year clinical experience. Southern Thoracic Surgical Association, Marco Island, FL, November 1994.
28. Murray GF, **Jones DR.** A comprehensive curriculum for thoracic surgery: Survey of opinions from program directors and residents. Thoracic Surgery Directors Association Annual Meeting, The Society of Thoracic Surgeons, Palm Springs, CA, January 1995.

29. **Jones DR.** Quality in graduate medical education: A resident's perspective. Annual AAMC ORR/CAS panel discussion on quality in graduate medical education. Washington, D.C., October 1995.
30. Hill RC, **Jones DR**, Kalantarian B, Vance RA. Selective lung ventilation during thoracoscopy: Effects of insufflation on hemodynamics. Southern Thoracic Surgical Association, San Antonio, TX, November 1995.
31. **Jones DR.** Can pulmonary microvascular integrity be maintained after death? Department of Surgery Grand Rounds, University of North Carolina School of Medicine, May 1996.
32. **Jones DR.** Induction chemoradiotherapy followed by esophagectomy for esophageal carcinoma: a Phase II study. Modern Techniques and Research in Cardiothoracic Surgery. Bowman Gray School of Medicine, Winston-Salem, NC, June 1996.
33. **Jones DR**, Becker RM, Lemasters JJ, Egan TM. Is pulmonary microvascular integrity maintained after death? Poster presentation, American College of Chest Physicians, San Francisco, CA, October 1996.
34. Lucas C, Mill MR, **Jones DR**, Lucas W, Yim P, Ha B, Wilcox BR. A lamb model of the Fontan circulation. Cardiovascular System Dynamics Society, Chapel Hill, NC, November 1996.
35. **Jones DR**, Hoffmann SC, Egan TM. Reduced ischemia-reperfusion injury (IRI) with isoproterenol in non-heart beating donor lungs. Poster presentation, Association for Academic Surgery, Chicago IL, November 1996.
36. **Jones DR**, Dettlerbeck FC, Egan TM, Parker LA Jr, Bernard SA, Tepper JE. Impact of chemoradiotherapy followed by surgery for patients with carcinoma of the esophagus. The Society of Thoracic Surgeons, San Diego, CA, January 1997.
37. **Jones DR**, Davidson AG, Hostetter RB, Murray GF. p53 and cyclin D1 as independent prognostic indicators in esophageal adenocarcinoma. Poster presentation, The Society of Thoracic Surgeons, San Diego, CA, January 1997.
38. Wilcox BR, **Jones DR**, Frantz EG, Brink LW, Henry GW, Mill MR, Anderson RH. An anatomically sound, simplified approach to repair of "complete" atrioventricular septal defect. The Society of Thoracic Surgeons, San Diego, CA, January 1997.
39. **Jones DR**, Hoffmann SC, Egan TM. Reduction of ischemia-reperfusion injury with isoproterenol in non-heart beating donor lungs. Womack Surgical Society, Chapel Hill, NC, January 1997.
40. **Jones DR.** Multimodality Therapy for Carcinoma of the Esophagus. Continuing Education Conference: "What's New in Thoracic Surgery?" Chapel Hill, North Carolina, May 1997.

41. **Jones DR.** Multi-modality therapy for carcinoma of the esophagus. Department of Surgery Grand Rounds, University of North Carolina School of Medicine, Chapel Hill, North Carolina, June 1997.
42. **Jones DR.** Role of computed tomography after induction chemoradiotherapy in patients with esophageal cancer. Society of Thoracic Radiology, San Juan, Puerto Rico, March 1998.
43. **Jones DR.** Induction of tumor chemosensitivity by inhibition of NF- $\kappa$ B. American Association of Cancer Research Special Conference, Whistler, British Columbia, Canada, March 1999.

### **Invited Lectures and Presentations University of Virginia**

#### International:

1. De Lange EE, Stoler Truwit JD, Daniel TM, **Jones DR**, Altes T, Mugler JP, Brookman JR. Hyperpolarized Helium-3 MR imaging, computed tomography and spirometry assessments in patients with emphysema: Comparison with histology. International Society of Magnetic Resonance in Medicine. Glasgow, Scotland April 2001.
2. DeLange EE, **Jones DR**, Altes TA, Daniel TM, Salerno MS, Brookeman JR, Mugler JP. Bronchiolitis obliterans following lung transplantation: evaluation with hyperpolarized helium-3-MR imaging. International Society of Magnetic Resonance in Medicine, Honolulu, HA, May 2002.
3. Denlinger CE, Mayo MW, **Jones DR**. Proteasome inhibition sensitizes NSCLC to generation of reactive oxygen species and cell death. 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, Canada, August 2003.
4. RR Bowman, SB Gay, TA Altes, PK Rehm, **DR Jones**, JM Olazagasti, JM Ciambotti, A Agarwal, TM Daniel. CT-guided radionuclide injection of small or ill-defined pulmonary nodules prior to thoracoscopic excisional biopsy: A procedure manual. (poster presentation) Association of University Radiologists, Montreal, Quebec, Canada, May 2005.
5. **Jones DR.** Management of Esophageal Surgical Disasters. The Vesuvian Interactive Thoracic Course. Citta Della Scienza, Naples, Italy September 2006.
6. **Jones DR.** Treatment for non-small cell lung cancer based on tumor cell genetic signatures: its time has come? Keynote Address, 66<sup>th</sup> Scientific Meeting of the Taiwan Surgical Association, Kaohsiung, Taiwan, March 2007.

7. **Jones DR.** Regulation of the Metastasis Suppressor Gene BRMS1 in Non-Small Cell Lung Cancer. National Taiwan University Hospital, Taipei, Taiwan, March 2007.
8. **Jones DR.** Video-assisted thoracic surgery (VATS) lobectomy: An update. Memorial Hospital, Taipei, Taiwan, March 2007.
9. **Jones DR.** Surgical treatment of esophageal cancer following induction therapy. Tri-service General Hospital, Taipei, Taiwan, March 2007.
10. **Jones DR.** Keys to a successful lung transplantation program. Tri-service General Hospital, Taipei, Taiwan, March 2007.
11. **Jones DR.** Surgical treatment of esophageal cancer following induction therapy. Tsu-Chi Buddhist Hospital, Hua Lien, Taiwan, March 2007.
12. Taylor MD, Nagji AK, Kozower BD, Daniel TM, **Jones DR.** Intermediate results of primary and redo transthoracic repairs of paraesophageal hernias. European Society of Thoracic Surgery, Leuven, Belgium, June 2007.
13. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD Lau CL, **Jones DR.** FDG-PET SUVmax and survival correlates with tumor markers in esophageal cancer. European Society of Thoracic Surgery, Bologna, Italy, June 2008.
14. **Jones DR.** Limited resections in early stage lung cancer. The XXXVI Brazilian Pneumology and Thoracic Surgery Meeting, Brasilia, Brazil, November 2008.
15. **Jones DR.** Sleeve lobectomy vs. pneumonectomy for NSCLC. The XXXVI Brazilian Pneumology and Thoracic Surgery Meeting, Brasilia, Brazil, November 2008.
16. **Jones DR.** Pancoast-Tobias resections: The posterior approach. The XXXVI Brazilian Pneumology and Thoracic Surgery Meeting, Brasilia, Brazil, November 2008.
17. **Jones DR.** Surgical management of esophageal cancer. The XXXVI Brazilian Pneumology and Thoracic Surgery Meeting, Brasilia, Brazil, November 2008.
18. **Jones DR.** Use of Adjuvant Therapy for Lung Cancer. European Society of Thoracic Surgery, ESTS/AATS Post-graduate Program. Krakow, Poland, May 2009.
19. Hennessy SA, Grogan EL, Harthun NL, **Jones DR**, Kozower BD, Lau CL. Symptomatic Pulmonary Emboli in Lung Transplant Recipients. International Society of Heart Lung Transplantation. Paris, France April, 2009.
20. **Jones DR.** Strategies to facilitate the introduction of minimally-invasive thoracic surgical (VATS) techniques into clinical practice. Istituto Nazionale per lo Studio e la Cura dei Tumori. 75<sup>th</sup> Anniversary of the National Cancer Institute of Italy, September 2009, Naples Italy.

21. **Jones DR.** Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Istituto Nazionale per lo Studio e la Cura dei Tumori. Keynote Address, 75<sup>th</sup> Anniversary of the National Cancer Institute of Italy, September 2009, Naples Italy.
22. **Jones DR.** Technical tricks for parenchymal-sparing lung surgery. Tongariro Cardiothoracic Surgery Meeting. Rotorua, New Zealand, March 2010.
23. **Jones DR.** Thymic Tumors. Tongariro Cardiothoracic Surgery Meeting. Rotorua, New Zealand, March 2010.
24. **Jones DR.** Legends behind cardiothoracic instrumentation. Tongariro Cardiothoracic Surgery Meeting. Rotorua, New Zealand, March 2010.
25. **Jones DR.** The road less travelled: moving from thoracotomy to VATS lobectomy. Tongariro Cardiothoracic Surgery Meeting. Rotorua, New Zealand, March 2010.
26. **Jones DR.** The role of limited (sublobar) resections in non-small cell lung cancer. Tongariro Cardiothoracic Surgery Meeting. Rotorua, New Zealand, March 2010.
27. Darling G, Allen MS, Decker P, Landreneau RJ, McKenna R, **Jones DR**, Incelet RI, Putnam JB, and the Z0030 Study Group. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: Results of the ACOSOG Z0030 trial. American Association of Thoracic Surgery, Toronto, Canada May 2010.
28. **Jones DR.** Basic science research in thoracic surgery. Developing the Academic Surgeon Symposium. American Association of Thoracic Surgery, Toronto, Canada May 2010.
29. LaPar DJ, Nagji A, Bhamidipati CM, Kozower BD, Lau CL, Ailawadi A, **Jones DR.** Season Variation Influences Outcomes Following Lung Cancer Resections. European Society of Thoracic Surgery, Valladolid, Spain May 2010.
30. **Jones DR.** Update on the pathobiology of Barrett's esophagus. ESTS Thoracic Surgery Post-graduate Course. European Society of Thoracic Surgery, Valladolid, Spain May 2010.
31. **Jones DR.** The impact and implication of volume of cases (Invited Lecture). European Society of Thoracic Surgery, Valladolid, Spain May 2010.
32. **Jones DR.** How to increase the chances of training in the United States. ESTS Training in Thoracic Surgery Symposium. European Society of Thoracic Surgery, Valladolid, Spain May 2010.

33. **Jones DR.** Advances in the surgical treatment of NSCLC. Satellite Symposium: New paradigms in adjuvant treatment in resected NSCLC. European Society of Thoracic Surgery, Valladolid, Spain May 2010.
34. **Jones DR.** Identification of small lung nodules: technique of radiotracer-guided thoroscopic biopsy. University of Toronto 35<sup>th</sup> Annual Thoracic Surgery Refresher Course, Toronto, Canada June 2010.
35. **Jones DR.** Integrating adjuvant therapy with surgery for non-small cell lung cancer. University of Toronto 35<sup>th</sup> Annual Thoracic Surgery Refresher Course, Toronto, Canada June 2010.
36. **Jones DR.** Do all patients require EUS and PET for the staging of esophageal cancer? (20<sup>th</sup> Annual R.D. Henderson Memorial Lecture) University of Toronto 35<sup>th</sup> Annual Thoracic Surgery Refresher Course, Toronto, Canada June 2010.
37. **Jones DR.** When is surgery an option in the management of metastatic lung cancer? University of Toronto 35<sup>th</sup> Annual Thoracic Surgery Refresher Course, Toronto, Canada June 2010.
38. **Jones DR.** Management of the malignant pleural effusion. University of Toronto 35<sup>th</sup> Annual Thoracic Surgery Refresher Course, Toronto, Canada June 2010.
39. **Jones DR.** Three technical tricks to avoid performing a pneumonectomy. University of Toronto 35<sup>th</sup> Annual Thoracic Surgery Refresher Course, Toronto, Canada June 2010.
40. Hucklenbruch C, Gottschalk A, Scalzo DC, Wang XQ, Gurka KK, **Jones DR**, Blank RS. Risk factors for the development of primary graft dysfunction after lung transplantation. 12th Capital City Conference of the DGAI - Congress of Anesthesiology and Intensive Care Medicine. Berlin, Germany September 2010.
41. Hucklenbruch C, Gottschalk A, Scalzo DC, Gurka KK, **Jones DR**, Jaeger JM, Blank RS. Impact of anesthetic factors on the risk of respiratory complications after pneumonectomy. 12th Capital City Conference of the DGAI - Congress of Anesthesiology and Intensive Care Medicine. Berlin, Germany September 2010.
42. **Jones DR.** Strategies to facilitate the introduction of minimally-invasive thoracic surgical (VATS) techniques into clinical practice. Taiyuan Pulmonary Hospital, Taiyuan China July 2011.

National:

1. **Jones DR**, Mayo MW, Marshall A, Baldwin AS. Chemosensitivity in NSCLC by NF- $\kappa$ B inhibition is Fas-independent. Surgical Forum, American College of Surgeons Surgical Forum, San Francisco, California, October 1999.



2. **Jones DR**, Broad MD, Madrid LK, Baldwin AS Jr., Mayo MA. Inhibition of chemotherapy-induced NF- $\kappa$ B activation in NSCLC enhances in vitro tumor cell death via apoptosis. Society of Thoracic Surgeons, Fort Lauderdale, FL, January 2000.
3. Broad RM, Parsons SJ, **Jones DR**. Chemotherapy-mediated apoptosis in NF- $\kappa$ B-deficient non-small cell lung cancer and the role of caspase activity. 16<sup>th</sup> Annual Meeting on Oncogenes and Tumor Suppressors. La Jolla, CA, June 2000.
4. **Jones DR**, Broad RM, Parsons SJ, Mayo MW. Chemotherapy-induced reactive oxygen species activate NF- $\kappa$ B and are required to induce apoptosis following the loss of NF- $\kappa$ B in NSCLC. American College of Surgeons Surgical Forum. Chicago, IL, October 2000.
5. Smith CD, **Jones DR**, Kern JA, et al. Beneficial Effects of Inhaled Nitric Oxide in Adult Cardiothoracic Surgical Patients. Southern Thoracic Surgical Association. Marco Island, FL November 2000.
6. **Jones DR**, Schottelius AJG, Madrid LV, Broad RM, Baldwin AS, Mayo MW. Chemotherapy-induced NF- $\kappa$ B activation in NSCLC occurs through an IKK-independent mechanism. American Association of Cancer Research. New Orleans, LA March 2001.
7. **Jones DR**, Broad RM, Parsons SJ, Mayo MW. Chemosensitization of NF- $\kappa$ B-deficient non-small cell lung cancer cells is mediated by increased cytochrome c release and caspase activation. American Association of Thoracic Surgery. San Diego, CA May 2001.
8. Broad RM, Mayo MW, **Jones DR**. Paclitaxel-mediated induction of NF- $\kappa$ B is a marker of chemoresistance in esophageal cancer cell lines. American College of Surgeons Surgical Forum. New Orleans, LA October 2001.
9. Salerno M., de Lange EE, Altes TA, Brookeman JR, **Jones DR**, Mugler III JP. High Temporal Resolution Interleaved-Spiral Dynamic Hyperpolarized Helium-3 MR Imaging of Patients with Lung Transplants: Assessment of Pulmonary Gas Flow as a Potential Method for Early Diagnosis of Rejection. Radiology Society of North America, November 2001.
10. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, **Jones DR**, Robbins MC, Kron IL. Ischemia-reperfusion injury following lung transplantation increases risk of late bronchiolitis obliterans syndrome. Southern Thoracic Surgical Association, San Antonio TX November 2001.
11. Denlinger CE, Broad RM, Reilly E, Mayo MW, **Jones DR**. Inhibition of histone deacetylation and NF- $\kappa$ B activation sensitizes NSCLC to undergo apoptosis. American College of Surgeons Surgical Forum. San Francisco, CA, October 2002.

12. **Jones DR**, Stiles BM, Denlinger CE, Antippa P, Daniel TM. Results and complications of pulmonary segmentectomy. Southern Thoracic Surgical Association, Miami, FL, November 2002.
13. Rich TA, Shepard RC, Cohn SM, **Jones DR**, Daniel TM. Clinical experience with daily capecitabine and celecoxib, combined with irradiation for cancer of the esophagus: widening the therapeutic window with “targeted” chemoradiation. American Radium Society Houston, TX, April 2003.
14. Denlinger CE, Broad RM, Mayo MW, **Jones DR**. Combined histone deacetylation and proteasome inhibition enhances apoptosis in non-small cell lung cancer. American Association of Thoracic Surgery. Boston, MA, May 2003.
15. Denlinger CE, Mayo MW, **Jones DR**. Combination proteasome inhibition and gemcitabine chemosensitizes NSCLC to apoptosis by inhibition of NF- $\kappa$ B. American Association of Cancer Research, Washington DC, July 2003.
16. Denlinger CE, Mayo MW, **Jones DR**. Akt is required for histone deacetylase inhibitor-induced activation of NF- $\kappa$ B. American Association of Cancer Research, Washington DC, July 2003.
17. Denlinger CE, Mayo MW, **Jones DR**. Pharmacological NF-kappa B inhibition sensitizes gemcitabine-resistant NSCLC to apoptosis. American College of Surgeons Surgical Forum. Chicago, IL, October 2003.
18. **Jones DR**. Management of sub-centimeter lung cancers. Symposium on CT screening for lung cancer. American College of Surgeons, Chicago, IL October 2003.
19. **Jones DR**. Pneumonectomy or sleeve resection: which is the operation of choice? Post-graduate course, Southern Thoracic Surgical Association, Bonita Springs, FL, November, 2003.
20. Denlinger CE, Rundall BK, Mayo MW, Keller MD, Kron IL, **Jones DR**. Proteasome inhibition sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis in vitro and in vivo. Society of Thoracic Surgeons, San Antonio, TX, January 2004.
21. Rundall BK, Denlinger CE, **Jones DR**. Combined Histone Deacetylase and NF- $\kappa$ B Inhibition Sensitizes Non-Small Cell Lung Cancer to Cell Death. Society of University Surgeons, St. Louis, MO February 2004.
22. Denlinger CE, Rundall BK, Keller MD, **Jones DR**. Proteasome inhibition sensitizes NSCLC to HDAC inhibitor-induced apoptosis through the generation of reactive oxygen species. American Association of Thoracic Surgery, Toronto, Canada, April 2004.

23. Rundall BK, Denlinger CE, **Jones DR**. Efficacy of histone deacetylase inhibitors in NSCLC is attenuated by NF- $\kappa$ B acetylation. American College of Surgeons, Surgical Forum, New Orleans, LA, October 2004.
24. **Jones DR**. Management of N2 disease at thoracotomy for non-small cell lung cancer: what to do? Post-graduate course, Southern Thoracic Surgical Association, Postgraduate course, Cancun, Mexico, November, 2004.
25. **Jones DR**, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME. Stage IB non-small cell lung cancers: Are they all the same? Southern Thoracic Surgical Association, Cancun, Mexico, November, 2004.
26. White H, Rich TA, **Jones DR**, Daniel TM, Brenin C, Shephard R. Preliminary Experience with External Irradiation Plus Capecitabine and Celebrex for Cancer of the Esophagus: Targeted Treatment with Low Morbidity. Radiological Society of North America, Chicago, IL, December 2004
27. Allen MS, Darling GE, Pechet TVT, Mitchell JD, Herndon II JE, Landreneau RJ, Incullet RI, **Jones DR**, Meyers BF, Putnam JB, Rusch VW and the ACOSOG Z0030 study group. Morbidity and Mortality of Major Pulmonary Resections in Patients With Early Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial. Society of Thoracic Surgeons, Ft. Lauderdale, FL, January 2005.
28. Rundall BK, Denlinger CE, **Jones DR**. Suberoylanalide hydroxamic acid combined with gemcitabine is pro-apoptotic in non-small cell lung cancer. Society of University Surgeons. Nashville, TN, February, 2005.
29. Rundall BK, Denlinger CE, **Jones DR**. Inhibition of PI3K/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. American Association of Thoracic Surgeons. San Francisco, CA, April 2005.
30. **Jones DR**, Vaughters ABR, Daniel TM, Shen KR, Heinzmann JL. Establishing institutional value: An assessment of the general thoracic surgery outpatient service. (Moderated Poster Presentation) Southern Thoracic Surgical Association, Orlando FL, November 2005.
31. **Jones DR**. Management of esophageal perforation. Post-graduate course, Southern Thoracic Surgical Association. Orlando, FL, November 2005.
32. RR Bowman, SB Gay, PK Rehm, TA Altes, JM Olazagasti, JM Ciambotti, A Agarwal, **DR Jones**, TM Daniel. Web-based demonstration of CT-guided radionuclide localization by injection of small or ill-defined pulmonary nodules prior to their thoracoscopic excisional biopsy. (educational exhibit) Radiological Society of North America, Chicago, IL, November 2005.

33. Smith PW, Parini V, Daniel TM, Shen KR, Robbins MK, Tribble CG, Kron IL **Jones DR.** Lung Transplantation in Patients 60 Years and Older: Results, Complications, and Outcomes. Society of Thoracic Surgeons. Chicago, IL January 2006.
34. Stiles BM, Altes TE, **Jones DR**, Shen KR, Gay SB, Olazagast J, Rehm P, Daniel TM. Clinical Experience with Radiotracer-Guided Thoracoscopic Biopsy of Small, Indeterminate Lung Nodules. Society of Thoracic Surgeons. Chicago, IL January 2006.
35. Liu Y, Smith PW, **Jones DR.** Breast cancer metastasis suppressor-1 (BRMS1) modulates NF-kappa B-dependent transcription via acetylation of RelA/p65. (Poster presentation) American Association of Cancer Research, Washington D.C. April 2006.
36. McDonough PB, **Jones DR**, Shen RK, et al. Does positron emission tomography add information to endoscopic ultrasound sonography and CT in the management of esophageal cancer? A prospective single center study. (Poster presentation) American College of Gastroenterology. Las Vegas NV, September, 2006.
37. **Jones DR.** Management of high-grade dysplasia. Contemporary General Thoracic Surgery. Washington University School of Medicine. St. Louis MO, October 2006.
38. **Jones DR.** Sleeve resection vs. Pneumonectomy. Contemporary General Thoracic Surgery. Washington University School of Medicine. St. Louis MO, October 2006.
39. **Jones DR.** Surgical management of severe esophageal strictures. Contemporary General Thoracic Surgery. Washington University School of Medicine. St. Louis MO, October 2006.
40. **Jones DR.** Pulmonary Segmentectomy. Contemporary General Thoracic Surgery. Washington University School of Medicine. St. Louis MO, October 2006.
41. **Jones DR.** Chest wall resection. Contemporary General Thoracic Surgery. Washington University School of Medicine. St. Louis MO, October 2006.
42. Smith PW, Hongkun Wang H, Gazoni LM, Shen KR, Daniel TM, **Jones DR.** Obesity Is Not Associated With Increased Risk Of Complications Following Anatomic Resection For Non-Small Cell Lung Cancer. Society of Thoracic Surgeons San Diego CA, January 2007.
43. **Jones DR.** Management of pulmonary carcinoids. Post-graduate course. Society of Thoracic Surgeons San Diego CA, January 2007.
44. **Jones DR.** Preparing the grant: Preliminary data. AATS/NIH Joint Conference on Grantsmanship. NIH, Bethesda MD, March 2007.
45. **Jones DR.** Surgical Management of Lung Cancer. William J. Smith Memorial Oncology Conference. Asheville, NC April 2007.

46. Ailawadi G, Smith PW, Oka T, Shen KR, Daniel TM, **Jones DR**. Effect of Induction Regimen on Acute Rejection and Bronchiolitis Obliterans Syndrome Following Lung Transplantation. American Association of Thoracic Surgery, Washington DC, May 2007.
47. Kozower BD, Meyers BF, Smith MA, DeOliveiria NC, Cassivi SD, Guthrie TJ, Conaway MR, Ryan BJ, Shen KR, **Jones DR**. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter review. American Association of Thoracic Surgery, Washington DC, May 2007.
48. Allen MS, Darling GE, Decker PA, Putnam JB, Malthaner RA, Inculet RI, **Jones DR**, McKenna RJ, Landreneau RJ. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial. American Society of Clinical Oncology, Chicago, IL, June 2007.
49. **Jones DR**. BRMS1-mediated regulation of metastasis in lung cancer. Visiting Research Professor, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, July 2007.
50. **Jones DR**. Surgical resection of lung cancer: intra-operative resection and staging via thoracotomy, technical tricks. American College of Surgeons Thoracic Surgery Post-Graduate Course. New Orleans, LA, October, 2007.
51. Kozower BD, Meyers BF, Reed CE, **Jones DR**, Decker PA, JB Jr. Does FDG-PET prevent nontherapeutic thoracotomies for clinical stage IA lung cancer? A subset analysis of the ACOSOG Z0050 trial. Southern Thoracic Surgical Association, Bonita Springs FL, November 2007.
52. **Jones DR**. Keys to a successful lung transplantation program. Invited Lecturer, Methodist Hospital, Houston, TX December, 2007.
53. **Jones DR**. Current management of lung cancer. Grand Rounds, Department of Surgery, West Virginia University School of Medicine, Morgantown, WV, December 2007.
54. **Jones DR**. Regulation of the BRMS1 gene in non-small cell lung cancer. Molecular and Cellular Biology Fall Seminar Series, Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown WV, December 2007.
55. Smith PW, Brix WK, Atkins KA, Taylor M, Theodosakis N, Kozower BD, **Jones DR**, Wick MR. Glucose Transporter-1 (GLUT1) expression and PET-CT-SUVmax in esophageal carcinomas. United States and Canadian Academy of Pathology, Denver CO, March 2008.
56. Brix WK, Ormsby WD, Smith PW, Theodosakis N, **Jones DR**, Wick MR, Conaway MA, Stelow EB. Response to neoadjuvant therapy and survival with pulmonary non-small cell carcinoma. United States and Canadian Academy of Pathology, Denver CO, March 2008.

57. **Jones DR.** Return on Investment: 15 years of TSFRE Funding. Society of Thoracic Surgical Education. Napa CA, March, 2008.
58. **Jones DR.** Integrating adjuvant therapy with surgery. Looking to the Future of Thoracic Surgery. American Association of Thoracic Surgery. San Diego, CA, May 2008.
59. Ailawadi G, Lau CL, Fedoruk LM, Smith PW, Kuhn C, Kozower BD, Kern JA, Peeler BB, Kron IL, **Jones DR.** Does reperfusion injury still cause significant mortality after lung transplantation? American Association of Thoracic Surgery. San Diego, CA, May 2008.
60. **Jones DR,** Taylor MD, Smith PW, Brix WK, Wick WR, Theodosakis N, Swenson BJ, Kozower BD, Lau CL. FDG-SUVmax correlates with increased expression of Glut1, p53, and EGFR in patients with non-small cell lung cancer. Western Thoracic Surgical Association, Kona, HA, June 2008.
61. **Jones DR.** Regulation of the Metastasis Suppressor Gene BRMS1 in Non-Small Cell Lung Cancer. American Association of Thoracic Surgery General Thoracic Surgery Biology Club. San Diego, CA, May 2008.
62. **Jones DR.** Localization of small nodules. Masters of Minimally-invasive Thoracic Surgery. Orlando, FL, September, 2008.
63. **Jones DR.** The future for lung cancer care is science. Masters of minimally-invasive thoracic surgery. Orlando, FL, September, 2008.
64. Panneerdoss S, Mandal A, Lui Y, Shetty J, Chertihin O, **Jones DR,** Frierson HF, Flickinger CJ, Herr JC. Expression of Sperm Fibrous Sheath Protein CABYR in Human Lung Cancer Tissues and Cancerous Cell Lines: A Potential Cancer-Testis Antigen Biomarker for Lung and Head and Neck Tumors. NIH-Fogarty Meeting, NIH, Bethesda, MD, October 2008.
65. **Jones DR.** Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Department of Surgery Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, New York, November 2008.
66. **Jones DR.** Surgical and molecular therapy for lung cancer. Society of Clinical Surgery 105<sup>th</sup> meeting, Charlottesville, VA, November 2008.
67. Kozower BD, Ailawadi G, **Jones DR,** Pates RD, Lau CL, Kron IL, Stukenborg GJ. A comparison of risk adjusted mortality models for adult cardiac surgery: the society of thoracic surgeon's database versus the university healthcare consortium. Society of Thoracic Surgeons, San Francisco, CA January, 2009.
68. **Jones DR.** Threats to the specialty – watch for back (esophagus). Post-graduate course. Society of Thoracic Surgeons San Francisco CA, January 2009.

69. Blank RS, Scalzo DC, Gurka KK, **Jones DR**, Jaeger JM. Anesthetic factors and the risk of respiratory complications after pneumonectomy. Society of Cardiovascular Anesthesiologists, San Antonio, TX April, 2009.
70. Panneerdoss S, Mandel A, Lui Y, Shetty J, Chertihin O, Suryavathi V, **Jones DR**, Frierson HF, Flickinger CJ, Herr JC. CABYR, and abundant sperm protein expresses in human lung cancer tissues and cell lines. Testis Workshop Philadelphia, PA, April 2009.
71. **Jones DR**. Basic science research in thoracic surgery. Developing the Academic Surgeon Symposium. American Association of Thoracic Surgery, Boston, MA May 2009.
72. **Jones DR**. The sole pathway leading to ABTS certification should be a comprehensive integrated cardiothoracic surgery training program beginning directly after medical school. Pro/Con debate. American Association of Thoracic Surgery, Boston, MA May 2009.
73. Taylor MD, Liu Y, Nagji AS, Theodosakis N, **Jones DR**. Combined proteasome and histone deacetylase inhibition upregulates e-cadherin metastasis suppressor gene expression and attenuates epithelial-mesenchymal transition in esophageal cancer. Western Thoracic Surgical Association Banff AB, Canada, June 2009.
74. Dunlap NE, Lerner JM, Read PW, Kozower BD, Lau CL, Sheng K, **Jones DR**. Size Matters: A Comparison Of T1 And T2 Peripheral Non-small Cell Lung Cancers Treated With Stereotactic Body Radiation Therapy (SBRT). Western Thoracic Surgical Association Banff AB, Canada, June 2009.
75. Scott WJ, Allen MS, Darling G, Meyers BF, Decker PA, Putnam JB, McKenna RW, Landreneau RJ, **Jones DR**, Inculet RI, Malthaner RA. Perioperative outcomes of video-assisted (VATS) for lung cancer compared to open thoracotomy: An analysis of data from the American College of Surgeons Oncology Group (ACOSOG) Z0030 clinical trial. Western Thoracic Surgical Association Banff AB, Canada, June 2009.
76. Panneerdoss S, Mandal A, Suryavathi V, Lui Y, Shetty J, Chaertihin O, **Jones DR**, Jameson MJ, Frierson HF, Flickinger CJ, Herr JC. Cancer-testis antigen CABYR in human lung cancers. Control of Cancer Immunosuppression: The challenge for cancer vaccine development. New York, NY, September 2009.
77. **Jones DR**. Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Department of Surgery Grand Rounds, The Earle W. Wilkins Lectureship, Massachusetts General Hospital November 2009.
78. Hennessy SA, Swenson BR, Kozower BD, **Jones DR**, Ailawadi G, Lau CL, Kron IL. Donor hyperoxia is associated with development of bronchiolitis obliterans following lung transplantation. Southern Thoracic Surgical Association, Marco Island FL, November 2009.
79. Kozower BD, Lau CL, Phillips JV, Burks SG, **Jones DR**, Stukenborg GJ. A Thoracic Surgeon Directed Tobacco Cessation Intervention. Southern Thoracic Surgical Association, Marco Island FL, November 2009.

80. **Jones DR.** The impact and implication of volume of cases. General Thoracic Surgical Symposia, Society of Thoracic Surgeons, Ft. Lauderdale, FL January, 2010.
81. Isbell JM, Deppen S, Massion PP, Deming SL, Dawes A, **Jones DR**, Grogan EL. Separating the wheat from the chaff: Is it time for a model that predicts benign disease in patients with pulmonary nodules? Society of Thoracic Surgeons, Ft. Lauderdale, FL January, 2010.
82. Hucklenbruch C, Scalzo DC, X. Wang X, Gurka KK, **Jones DR**, Blank RS. Risk factors for the development of primary graft dysfunction after pulmonary transplantation surgery. International Anesthesia Research Society, Honolulu, HA, March 2010.
83. **Jones DR.** The legends behind cardiothoracic surgical instruments. Society of Thoracic Surgical Education, Sedona AZ, March 2010.
84. **Jones DR.** Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Department of Surgery Grand Rounds, Duke University April 2010.
85. Hennessy SA, Hranjec T, Kozower BD, **Jones DR**, Lau CL. Postoperative dialysis is a highly fatal complication in lung transplant recipients. International Society of Heart and Lung Transplantation. Chicago IL, April 2010.
86. LaPar DJ, Bhamidipati CM, Mery CM, Stukenborg GJ, **Jones DR**, Schirmer BD, Ailawadi G, Kron IL. Primary payer status affects mortality for major surgical operations. American Surgical Association Chicago IL, April 2010.
87. Nagji AS, Cho SH, Liu Y, Lee JK, **Jones DR.** Use of the “coexpression extrapolation” algorithm to identify tumor biomarkers that predict drug sensitivity to Vorinostat and Velcade in non-small cell lung cancer. American Association of Cancer Research, Washington DC, April 2010.
88. Nagji AS, Liu Y, Stelow EB, Stukenborg GJ, **Jones DR.** *BRMS1* promoter methylation correlates with decreased expression of BRMS1 in non-small cell lung cancer. American Association of Cancer Research, Washington DC, April 2010.
89. Liu Y, Nagji AS, Taylor MD, **Jones DR.** Proteasome inhibitor bortezomib induces E-cadherin re-expression through inhibiting NF- $\kappa$ B mediated DNA methylation in esophageal cancer. American Association of Cancer Research, Washington DC, April 2010.
90. Hennessy SA, Hranjec T, Kozower BD, **Jones DR**, Lau CL. Postoperative dialysis is a highly fatal complication after lung transplantation. International Society of Heart and Lung Transplantation, Chicago, IL April 2010.
91. **Jones DR.** Basic science research in thoracic surgery. Developing the Academic Surgeon Symposium. American Association of Thoracic Surgery, Toronto, Canada May 2010.



92. **Jones DR.** Tools and techniques for incorporating VATS into your practice. Industry-sponsored symposium, American Association of Thoracic Surgery, Toronto, Canada May 2010.
93. Emaminia A, Hennessy SA, Hranjec T, Kozower BD, **Jones DR**, Kron IL, Lau CL. Bronchiolitis obliterans is increased in the post-lung allocation score era. American Transplant Congress, San Diego, CA May 2010.
94. Fibla JJ, Cassivi SD, Decker PA, Allen MS, Darling GE, Landreneau RJ, McKenna RJ, **Jones DR**, Inculet RI, Putnam JB. Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). American Society of Clinical Oncology, Chicago IL, June 2010.
95. Harthun N, Kozower BD, **Jones DR**, Lau CL. The incidence of pulmonary neoplasms discovered by serial CT scanning following endovascular AAA repair. Society of Vascular Surgery, Boston MA, June 2010.
96. LaPar DJ, Bhamidipati CM, Kozower BD, **Jones DR**, Kron IL, Ailawadi G, Lau CL. Gender, race, and socioeconomic status affects outcomes following lung cancer resections in the United States. Society of Thoracic Surgeons (Poster presentation). San Diego, CA January 2011.
97. Hennessey SA, Hranjec T, Emaminia A, LaPar DJ, Kozower BD, **Jones DR**, Kron IL, Lau CL. Geographic distance between donor and recipient does not influence bronchiolitis obliterans syndrome after lung transplantation. Society of Thoracic Surgeons (Poster presentation). San Diego, CA January 2011.
98. LaPar DJ, Stukenborg GJ, Lau CL, **Jones DR**, Kozower BD. Does preoperative pulmonary function impact long term survival following lung cancer resection? Society of Thoracic Surgeons (Poster presentation), San Diego, CA January 2011.
99. Zhao Y, Turlington M, Steidle J, Kron IL, **Jones DR**, Pu L, Lau CL. Potential novel therapeutic compounds for non-small cell lung cancer. Society of Thoracic Surgeons (Poster presentation). San Diego, CA January 2011.
100. **Jones DR.** Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Department of Cardiothoracic Surgery Grand Rounds, Mount Sinai University December, 2010.
101. Nagji AS, Stukenborg GJ, Peluso MR, Taylor MD, Kozower BD, Lau CL, **Jones DR**. Predictors of hospital discharge to extended care facility following major general thoracic surgery. Society of Thoracic Surgeons (Poster presentation), San Diego, CA January, 2011.
102. LaPar DJ, Bhamidipati CM, Kozower BD, **Jones DR**, Kron IL, Ailawadi G, Lau CL. Gender, race, and socioeconomic status affects outcomes following lung cancer

- resections in the United States. Society of Thoracic Surgeons (Poster presentation), San Diego, CA January, 2011.
103. Hennessey SA, Hranjec T, Emamina A, LaPar DJ, Kozower BD, **Jones DR**, Kron IL, Lau CL. Geographic distance between donor and recipient does not influence bronchiolitis obliterans syndrome after lung transplantation. Society of Thoracic Surgeons (Poster presentation), San Diego, CA January, 2011.
  104. LaPar DJ, Stukenborg GS, Lau CL, **Jones DR**, Kozower BD. Does preoperative pulmonary function impact long-term survival following lung cancer resection? Society of Thoracic Surgeons (Poster presentation), San Diego, CA January, 2011.
  105. Zhao Y, Turlington M, Steidle J, Kron IL, **Jones DR**, Pu C, Lau CL. Potential novel therapeutic compounds for non-small cell lung cancer. Society of Thoracic Surgeons (Poster presentation), San Diego, CA January, 2011.
  106. **Jones DR**. Developing a research program in academic medicine. Grant Writing Workshop. American Association of Thoracic Surgery, Bethesda, MD March 2011.
  107. **Jones DR**. Research strategy – Innovation – How to make your grant new and unique. Grant Writing Workshop. American Association of Thoracic Surgery, Bethesda, MD March 2011.
  108. Emamina A, Hranjec T, Kozower BD, **Jones DR**, Kron IL, Lau CL. High lung allocation score is not a determinant of morbidity and mortality among pulmonary fibrosis and chronic obstructive pulmonary disease patients. American Transplant Congress, Philadelphia, PA May 2011.
  109. Nagji AN, Liu Y, Wei C, Xiao A, **Jones DR**. Ingenuity Pathway Analysis: Discovery of BRMS1 as a novel regulator of epithelial-to-mesenchymal transition in NSCLC. American Association of Thoracic Surgery, Philadelphia, PA May 2011.
  110. Fernando H, Landreneau R, Mandrekar S, Hillman S, Nichols F, DiPetrillo T, Heron D, Meyers B, **Jones DR**, Starnes S, Putnam JB. Thirty and ninety day outcomes after sublobar resection for non-small cell lung cancer (NSCLC); results from a multicenter phase III study. American Association of Thoracic Surgery, Philadelphia, PA May 2011.
  111. Emamina A, Hranjec T, Kozower BD, **Jones DR**, Kron IL, Lau CL. Development of bronchiolitis obliterans syndrome is not associated with primary diagnosis. American Thoracic Society, Denver CO, May 2011.
  112. Harpole D, Ballman KV, Oberg AL, Whiteley G, Cerfolio R, Keenan R, **Jones DR**, D'Amico TA, Shrager J, Putnam JB. Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. American Society of Clinical Oncology, Chicago, IL May 2011.

113. **Jones DR.** Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Department of Surgery Grand Rounds, Northwestern University, Chicago, IL May 2011.
114. LaPar DJ, Bhamidipati CM, Stukenborg GJ, Upchurch Jr GR, **Jones DR**, Hanks JB, Schirmer BD, Kron IL, Ailawadi GA. Predictors of elderly patient discharge to alternative care facilities following major surgical operations. American College of Surgeons, Surgical Forum, San Francisco, CA October 2011.
115. Taylor MD, Nagji AS, Petroni GR, Theodosakis N, Kozower BD, Lau CL, **Jones DR.** What are the predictors of recurrence following an R0 resection for non-small cell lung cancer? Southern Thoracic Surgical Association San Antonio, TX November 2011.
116. **Jones DR**, Wei C, Kozower BD, Lau CL, Stukenborg GS. Pathologic lymph node ratio is superior to nodal staging as a prognostic indicator of survival in esophageal cancer. Southern Thoracic Surgical Association San Antonio, TX November 2011.
117. LaPar DJ, Kron IL, **Jones DR**, Stukenborg GJ, Kozower BD. Hospital Procedure Volume Should Not Be Used as a Measure of Surgical Quality. American Surgical Association San Francisco, CA April 2012.
118. Bhamidipati CO, Stukenborg GJ, Ailawadi G, Lau CL, Kozower BD, **Jones DR.** Pulmonary resections performed at cardiothoracic surgery teaching hospitals have superior outcomes. American Association for Thoracic Surgery San Francisco, CA May 2012 .
119. Grogan EL, Deppen SA, Andrade G, Verdail F, Aldrich M, Chen H, BallmanKV, Decker P, Harpole D, Cerfolio R, Keenan R, **Jones DR**, D'Amico TA, Shrager J, Meyers B, Putnam JB. Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial. American Society of Clinical Oncology Chicago, IL June 2012.

Regional and Local:

1. **Jones DR.** Staging of non-small cell lung cancer. Fauquier County Medical Society. Warrenton, VA, October 1999.
2. **Jones DR.** Chemotherapy-induced NF- $\kappa$ B activation: A novel mechanism of chemoresistance in NSCLC. Hematology-Oncology Grand Rounds, University of Virginia, November 1999.
3. **Jones DR.** "Management of the Solitary Nodule" Winchester Medical Center. Winchester, VA December 1999.
4. **Jones DR.** Lung Cancer 2000; A New Millennium. Department of Medicine Grand Rounds, University of Virginia, February 2000.

5. **Jones DR**, Broad RM, Parsons SJ. Chemosensitization in NSCLC after NF- $\kappa$ B inhibition is caspase-dependent and Fas-independent. American Cancer Society, Virginia Chapter. Eastern Virginia School of Medicine, Norfolk, VA, March 2000.
6. **Jones DR**. Combined modality treatment of lung cancer. Clinch Valley Medical Center, Richlands, VA April 2000.
7. **Jones DR**. Management of the solitary pulmonary nodule. Danville Regional Medical Center, Danville, VA April 2000.
8. **Jones DR**. Surgical management of esophageal diseases. Bluefield Regional Medical Center. Bluefield, WV June 2000.
9. **Jones DR**. Surgical and radiographic staging of non-small-cell lung cancer. Appalachian Regional Hospital Beckley, WV June 2000.
10. **Jones DR**. Surgical management of esophageal diseases. Rockingham Memorial Hospital, Harrisonburg, VA January 2001.
11. **Jones DR**. Tumors of the Trachea. Otolaryngology Grand Rounds. University of Virginia. February 2001.
12. **Jones DR**. Pulmonary Resection in the High Risk Patient: Alternatives and Strategies. Current Approaches in Cancer Therapy Seminar. Williamsburg, VA March 2001.
13. **Jones DR**. Radiographic and surgical staging of non-small cell lung cancer. Martha Jefferson Hospital, Charlottesville, VA March 2001.
14. **Jones DR**, Stiles B, Antippa P, Daniel TM. Pulmonary segmentectomy: indications, results, and complications. Virginia Surgical Society. Fairfax, VA May 2001.
15. **Jones DR**. Thoracic Oncology Program. UVA Cancer Center Board. University of Virginia. Charlottesville, VA November 2001.
16. **Jones DR**. Radiographic and surgical staging in non-small cell lung cancer. Lung Cancer: Maximizing Technology & Therapy in the New Millennium (CME course). University of Virginia, Charlottesville, VA November, 2001.
17. **Jones DR**. Staging of Lung Cancer. Rockingham Memorial Hospital, Harrisonburg, VA January, 2002.
18. **Jones DR**. Lung Cancer 2001: The New Millennium. Mary Washington Hospital, Fredricksburg, VA January 2002.
19. **Jones DR**. Lung cancer 2002: surviving the perfect storm. Ned Shott Cancer Conference, Bluefield Regional Hospital. Bluefield, WV, April 2002.

20. **Jones DR.** Pulmonary resection in the high-risk patient: alternatives and strategies. Department of Surgery Grand Rounds, West Virginia University School of Medicine, Morgantown, WV, May 2002.
21. **Jones DR.** Surgical management of esophageal cancer. Department of Otolaryngology Grand Rounds, University of Virginia School of Medicine, Charlottesville VA, May 2002.
22. **Jones DR.** Pulmonary resection in the high-risk patient: alternatives and strategies. Department of Surgery Grand Rounds, University of Virginia School of Medicine, Charlottesville, VA, August 2002.
23. **Jones DR.** Pulmonary resection in the high-risk patient: alternatives and strategies. Lewis Gale Hospital, Salem, VA September 2002.
24. **Jones DR.** Pulmonary resection in the high-risk patient: alternatives and strategies. Missouri Baptist Hospital, St. Louis, MO October 2002.
25. **Jones DR.** Pulmonary resection in the high-risk patient: alternatives and strategies. Roanoke Virginia Oncology Bureau, Roanoke, VA October 2002.
26. **Jones DR.** Lung Transplantation. Department of Anesthesiology Grand Rounds. University of Virginia School of Medicine, Charlottesville, VA, November 2002.
27. **Jones DR.** Lung transplantation: surgical procedure and complications. Lung transplantation in the new millennium (CME conference). University of Virginia, Charlottesville, VA, February 2003.
28. Denlinger CE, Mayo MW, **Jones DR.** Combined proteasome and HDAC inhibition sensitizes NSCLC to apoptosis. American Cancer Society, Virginia Chapter. Charlottesville, VA March 2003.
29. Denlinger CE, Mayo MW, **Jones DR.** Proteasome inhibition sensitizes NSCLC to gemcitabine-induced apoptosis. Virginia Surgical Society Williamsburg, VA, April 2003.
30. **Jones DR.** Making Sense of Lung Cancer Treatment Strategies in 2003. Princeton Community Hospital, Princeton, WV June 2003.
31. Denlinger CD, Mayo MW, Yeung F, Keller MD, **Jones DR.** Akt inhibition sensitizes non-small cell lung cancer to HDAC inhibitor-induced apoptosis. Department of Surgery Resident Research Day. Charlottesville, VA June 2003.
32. **Jones DR.** Surgical management of complicated reflux disease. Digestive Health Center, University of Virginia, Charlottesville, VA October 2003.

33. **Jones DR.** Knocking out lung cancer's survival signals: a novel therapy for lung cancer. Evidence-based management of lung cancer (CME course). University of Virginia, Charlottesville, VA October 2003.
34. Denlinger CE, Rundall BK, **Jones DR**, Daniel TM, Hanks JB. Selective use of manubrial division for excision of substernal goiters. American College of Surgeons, Virginia Chapter, Charlottesville, VA, April 2004.
35. Denlinger CE, Rundall BK, Mayo MW, **Jones DR.** Akt inhibition sensitizes non-small cell lung cancer to HDAC inhibitor-induced apoptosis. American College of Surgeons, Virginia Chapter, Charlottesville, VA, April 2004. (1<sup>st</sup> Place cancer basic science award)
36. Denlinger CE, Rundall BK, **Jones DR.** Efficacy of histone deacetylase inhibitors in NSCLC is attenuated by NF- $\kappa$ B acetylation. University of Virginia, Resident Research Day, Charlottesville, VA, April 2004.
37. **Jones DR.** Malignant pleural effusions: management and future alternative therapies. Martha Jefferson Hospital Grand Rounds. Charlottesville, VA, June 2004.
38. **Jones DR.** What's new in thoracic surgery. Department of Anesthesia Grand Rounds. University of Virginia, July, 2004.
39. **Jones DR.** Strategies for lung parenchymal-sparing surgery in NSCLC. Virginia Thoracic Society. Richmond VA, October 2004.
40. **Jones DR.** Pre-operative evaluation of the thoracic surgery patient. Virginia Thoracic Society. Richmond VA, October 2004.
41. **Jones DR.** Management of esophageal tumors. Department of Otolaryngology Grand Rounds, University of Virginia School of Medicine, Charlottesville VA, November 2004.
42. **Jones DR.** Update on General Thoracic Surgery. Raleigh County Medical Association. Beckley WV, January 2005.
43. **Jones DR.** What's new in General Thoracic Surgery at UVA. Mary Washington Hospital Cancer Committee, Fredricksburg VA, March 2005.
44. **Jones DR.** What's new in General Thoracic Surgery at UVA. Richmond Pulmonary Associates, Richmond VA, April 2005.
45. **Jones DR.** Building a General Thoracic Surgery Program: The University of Virginia's Experience. First Annual Gordon F. Murray Lectureship. Nemaquin Woods, Farmington PA, May 2005.
46. **Jones DR.** Update on lung volume reduction surgery. Princeton Community Hospital, Princeton, WV July 2005.

47. **Jones DR.** University of Virginia Thoracic Oncology Program. Presentation for Friends of the Cancer Center. University of Virginia, Charlottesville, VA, September 2005.
48. **Jones DR.** Management of the high-risk thoracic surgery patient. Pulmonary Medicine Conference. South Boston, VA. October 2005.
49. **Jones DR.** The role of the metastasis suppressor gene BRMS1 in regulating NF- $\kappa$ B transcription in non-small cell lung cancer. UVA Cancer Center Seminar. University of Virginia, Charlottesville, VA, March 2006.
50. Smith PW, Liu Y, **Jones DR.** Breast cancer metastasis suppressor 1 (BRMS1) modulates NF- $\kappa$ B-dependent transcriptional activity. 5<sup>th</sup> Annual Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA, March 2006.
51. **Jones DR.** Management of Esophageal Cancer at UVA: A comparison with NSIQP. Department of Surgery Grand Rounds, University of Virginia School of Medicine, Charlottesville VA, August 2006.
52. **Jones DR.** BRMS1-mediated regulation of metastasis in lung cancer. Lung Cancer Research Conference, University of Virginia, Charlottesville, VA, January, 2007.
53. **Jones DR.** Understanding lung cancer metastasis: The role of the metastasis suppressor gene BRMS1. UVA Cancer Center Seminar Series, University of Virginia, Charlottesville, VA February, 2007.
54. **Jones DR.** Update on VATS lobectomy. Perioperative Services, Operating Room, University of Virginia, April, 2007.
55. **Jones DR.** New perspectives in lung cancer treatment. Elkins, WV, April, 2008.
56. Taylor MD, Liu Y, **Jones DR.** N-terminal region of RelA/p65 inhibits Sp1-mediated E-cadherin transcription in esophageal cancer. 7<sup>th</sup> Annual Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA, April 2008.
57. Liu Y, Taylor MD, Mayo MW, Smith PW, **Jones DR.** RelA/p65 actively represses BRMS1 transcription via recruitment of DNA and histone methyltransferases to chromatin. University of Virginia School of Medicine Faculty Research Retreat. Charlottesville, VA February, 2009.
58. Panneerdoss S, Mandal A, Liu Y, Sheety J, Chertihin O, Suryavathi V, **Jones DR,** Frierson HJ, Flickinger CJ, Herr JC. CABYR, an abundant sperm protein expresses in human lung cancer tissues and cell lines. University of Virginia School of Medicine Faculty Research Retreat. Charlottesville, VA February, 2009.
59. **Jones DR.** A Novel Role for RelA/p65: Active Transcriptional Repression Via Recruitment of DNA and Histone Methyltransferases to Chromatin. University of Virginia Cancer Center Seminar. University of Virginia, Charlottesville VA April 2009.

60. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Lau CL, **Jones DR**. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2009.
61. Smith PW, Liu Y, Siefert SA, Moskaluk CA, Petroni GR, **Jones DR**. Breast cancer metastasis suppressor gene 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2009.
62. Taylor MD, Liu Y, Nagji AS, Theodosakis N, **Jones DR**. Combined proteasome and histone deacetylase inhibition upregulates e-cadherin metastasis suppressor gene expression and attenuates epithelial-mesenchymal transition in esophageal cancer. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2009 (poster presentation).
63. Panneerdoss S, Mandel A, Lui Y, Shetty J, Chertihin O, Suryavathi V, **Jones DR**, Frierson HF, Flickinger CJ, Herr JC. Cancer testis antigen CABYR: A potential biomarker for lung cancer. The Carter Immunology Center Faculty Retreat. University of Virginia, Charlottesville, VA. June 2009.
64. **Jones DR**. Thoracic Oncology Program. University of Virginia Cancer Center Executive Committee. University of Virginia, Charlottesville, VA September 2009.
65. **Jones DR**. Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. Department of Surgery Grand Rounds, University of Virginia, Charlottesville, VA, October 2009.
66. **Jones DR**. Introduction of molecularly-targeted therapies for lung cancer by surgeons: The road less travelled. UVA Cancer Center (Patients and Friends), University of Virginia, Charlottesville, VA, October 2009.
67. **Jones DR**. Stepping up and stepping down in academic medicine. University of Virginia Leadership in Academic Medicine Forum. University of Virginia, Charlottesville, VA, November, 2009.
68. Nagji AS, Liu Y, Stelow EB, Stukenborg GJ, **Jones DR**. *BRMS1* transcriptional repression correlates with decreased expression of BRMS1 in non-small cell lung cancer. Virginia Surgical Society, Roanoke VA, April 2010.
69. Nagji AS, Cho SH, Liu Y, Lee JK, **Jones DR**. Use of the “coexpression extrapolation” algorithm to identify tumor biomarkers that predict drug sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Virginia Surgical Society, Roanoke VA, April 2010.



70. Nagji AS, Liu Y, Stelow EB, Stukenborg GF, **Jones DR**. BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathologic stage in non-small cell lung cancer. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2010.
71. LaPar DF, Bhamidipati CM, Mery CM, Stukenborg GF, **Jones DR**, Schirmer BD, Kron IL, Ailawadi G. Primary Payer Status Affects Outcomes for Major Surgical Operations. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2009.
72. Bhamidipati CM, LaPar DJ, Nagji A, , Kozower BD, Lau CL, Ailawadi A, **Jones DR**. Academic Season Does Not Affect Mortality Following Pulmonary Resection at Thoracic Surgery Teaching Hospitals. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2010 (poster presentation).
73. Taylor MD, Nagji AS, Lau CL, Kozower BD, **Jones DR**. What are the predictors of recurrence following an R0 resection for non-small cell lung cancer? Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2010 (poster presentation)
74. Yang Z, Liu Y, **Jones DR**, Kron IL. Acute hyperglycemia abolishes cardioprotective effect of ischemic pre-conditioning by inhibiting Akt phosphorylation. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2010 (2<sup>nd</sup> place - poster presentation).
75. **Jones DR**. Mentorship in Surgery. Women in Surgery; a Career Development Seminar for Women in Surgery. University of Virginia, Charlottesville, VA June 2011.
76. **Jones DR**. Building a National Reputation. Women in Surgery; a Career Development Seminar for Women in Surgery. University of Virginia, Charlottesville, VA June 2011.
77. **Jones DR**. Surgical treatment options for lung cancer. 2011 Lung Cancer Symposium. Princeton, WV September 2011.
78. Nagji A, **Jones DR**. Ingenuity Pathway Analysis: Discovery of BRMS1 as a novel regulator of epithelial-to-mesenchymal transition in NSCLC. Department of Surgery Resident Research Day, University of Virginia, Charlottesville, VA April 2012.

### **Motion Pictures**

1. **Jones DR**, Graeber GM. The technique of thoracoscopic lung biopsy. Subject-Oriented Motion Picture Symposium: Thoracoscopy. American College of Surgeons, New Orleans, LA, October 1992.

2. **Jones DR**, Genecov DG, Santascov R, Graeber GM. Thoracoscopic double pericardial window for drainage of recurrent effusions. Thoracic Surgery Motion Picture Session, American College of Surgeons, Chicago, IL, October 1994.
3. Parrino PE, **Jones DR**, Daniel TM, Hanks JB. Thoracoscopic resection of a mediastinal parathyroid adenoma. Virginia Surgical Society, Hot Springs, VA, April 2002.
4. Parrino PE, Ronson, R, **Jones DR**, Daniel TM, Hanks JB. Thoracoscopic resection of a mediastinal parathyroid adenoma. Thoracic Surgery Motion Picture Session, American College of Surgeons, San Francisco, CA, 2002.
5. Denlinger CE, Parrino PE, Angle JF, Daniel TM, Matsumoto A, **Jones DR**. Resection of a mediastinal Castleman's tumor: a multimodality approach. Thoracic Surgery Motion Picture Session, American College of Surgeons, Chicago, IL, 2003.
6. Julien MA, Dunnington GH, Kozower BD, **Jones DR**, Lau CL. Laparoscopic repair of a giant Morgagni hernia. Thoracic Surgery Motion Picture Session. Society of Thoracic Surgeons, San Diego, CA January 2011.

#### **Electronic publications**

1. Daniel TM, **Jones DR**. Videomediastinoscopy. General thoracic experts' techniques. CTSnet (available at <http://www.ctsnet.org/>) January 2003.